Vorinostat (SAHA)

For research use only. Not for use in humans.

目录号：S1047 别名： MK0683, Suberoylanilide hydroxamic acid 中文名称：伏立诺他

CAS No. 149647-78-9

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683)是一种HDAC抑制剂，无细胞试验中IC50为~10 nM。Vorinostat 会抑制高效的HPV-18 DNA扩增。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1558.77	现货
200mg	RMB 1198.15	现货
500mg	RMB 1794.86	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Vorinostat (SAHA)发表文献454篇：

Cell, 2020, S0092-8674(20)31394-5

PubMed: 33147445 ( click the link to review the publication )

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(4):599-617 e7

PubMed: 32243837 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(3):536-548.e21

PubMed: 29961578 ( click the link to review the publication )

Cell Metab, 2018, 5;27(6):1294-1308.e7

PubMed: 29754954 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 21(10):1163-71

PubMed: 26390243 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 28;158(5):989-999.

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 10;471(7337):235-9.

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4404

PubMed: 34285225 ( click the link to review the publication )

Neuro Oncol, 2021, 23(3):376-386

PubMed: 33130903 ( click the link to review the publication )

Neuro Oncol, 2021, 23(2):226-239

PubMed: 32822486 ( click the link to review the publication )

EMBO Mol Med, 2021, 13(8):e13901

PubMed: 34289240 ( click the link to review the publication )

Elife, 2021, 10e63810

PubMed: 33835029 ( click the link to review the publication )

Elife, 2021, 10e65654

PubMed: 34379055 ( click the link to review the publication )

J Colloid Interface Sci, 2021, 603:319-332

PubMed: 34186407 ( click the link to review the publication )
Oncogene, 2021, 10.1038/s41388-021-01931-1

PubMed: 34247191 ( click the link to review the publication )

EBioMedicine, 2021, 69:103457

PubMed: 34224975 ( click the link to review the publication )

Cancer Lett, 2021, 521:268-280

PubMed: 34481935 ( click the link to review the publication )

Cancer Lett, 2021, 512:28-37

PubMed: 33971281 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5781

PubMed: 34431104 ( click the link to review the publication )

Cancers (Basel), 2021, 13(15)3862

PubMed: 34359763 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2021, 10.1111/pcmr.13014

PubMed: 34482636 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):532

PubMed: 34031358 ( click the link to review the publication )

Cells, 2021, 10(5)1001

PubMed: 33923163 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.MCT-21-0066-A.2021

PubMed: 34552007 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:682561

PubMed: 34179011 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(14):17978-18005

PubMed: 34253688 ( click the link to review the publication )

Pharmacol Res, 2021, 171:105787

PubMed: 34314859 ( click the link to review the publication )

Front Oncol, 2021, 11:723966

PubMed: 34604061 ( click the link to review the publication )

J Virol, 2021, JVI0085321

PubMed: 34232065 ( click the link to review the publication )

Biochem Pharmacol, 2021, 188:114546

PubMed: 33838133 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(9)4559

PubMed: 33925399 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(7)3621

PubMed: 33807238 ( click the link to review the publication )

Sci Rep, 2021, 11(1):6270

PubMed: 33737539 ( click the link to review the publication )

J Enzyme Inhib Med Chem, 2021, 36(1):34-47

PubMed: 33100043 ( click the link to review the publication )

Brain Res Bull, 2021, 172:79-88

PubMed: 33895270 ( click the link to review the publication )

Genes (Basel), 2021, 12(2)260

PubMed: 33670166 ( click the link to review the publication )

Sci China Life Sci, 2021, 10.1007/s11427-020-1855-4

PubMed: 33420926 ( click the link to review the publication )

Transl Oncol, 2021, 14(10):101181

PubMed: 34298440 ( click the link to review the publication )
Transl Oncol, 2021, 14(1):100982

PubMed: 33395748 ( click the link to review the publication )

Reprod Sci, 2021, 10.1007/s43032-021-00533-2

PubMed: 33725312 ( click the link to review the publication )

Naunyn Schmiedebergs Arch Pharmacol, 2021, 10.1007/s00210-021-02140-z

PubMed: 34415354 ( click the link to review the publication )

Neurosci Lett, 2021, 764:136241

PubMed: 34509565 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2021, S0360-3016(21)02625-0

PubMed: 34348174 ( click the link to review the publication )

EBioMedicine, 2021, 65:103241

PubMed: 33647768 ( click the link to review the publication )

Exp Hematol Oncol, 2021, 10(1):19

PubMed: 33663586 ( click the link to review the publication )

Medicina (Kaunas), 2021, 57(5)456

PubMed: 34066975 ( click the link to review the publication )

J Dermatol Sci, 2021, S0923-1811(21)00005-0

PubMed: 33531202 ( click the link to review the publication )

AAPS J, 2021, 23(5):101

PubMed: 34403034 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(21):2001364

PubMed: 33173727 ( click the link to review the publication )

Sci Adv, 2020, 6(33):eaba6617

PubMed: 32851167 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa088

PubMed: 32107550 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(2)e001037

PubMed: 33158915 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(1)

PubMed: 31940587 ( click the link to review the publication )

Theranostics, 2020, 1;10(3):1433-1453

PubMed: 31938073 ( click the link to review the publication )

Cancer, 2020, 1;126(9):2024-2033

PubMed: 31999837 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Clin Epigenetics, 2020, 12(1):13

PubMed: 31941522 ( click the link to review the publication )

Br J Cancer, 2020, 27

PubMed: 32336756 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 17;8:158

PubMed: 32258036 ( click the link to review the publication )
J Neuroinflammation, 2020, 22;17(1):125

PubMed: 32321538 ( click the link to review the publication )

ACS Infect Dis, 2020, 29

PubMed: 32347704 ( click the link to review the publication )

Cancer Sci, 2020, 111(12):4429-4441

PubMed: 33043499 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:296

PubMed: 32195191 ( click the link to review the publication )

J Virol, 2020, 4;94(10) pii: e01923-19

PubMed: 32161174 ( click the link to review the publication )

Biochem Pharmacol, 2020, 3;178:114067

PubMed: 32504550 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

HIV Med, 2020, 21(11):747-757

PubMed: 33369029 ( click the link to review the publication )

Am J Transl Res, 2020, 12(10):6187-6203

PubMed: 33194023 ( click the link to review the publication )

Andrology, 2020, 10.1111/andr.12922

PubMed: 33064925 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):28

PubMed: 32028887 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12864

PubMed: 32733053 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2020, 188:110753

PubMed: 31884084 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(4):615-627

PubMed: 32322466 ( click the link to review the publication )

Cancer Sci, 2020, 111(7):2374-2384

PubMed: 32391602 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01394-w

PubMed: 32709923 ( click the link to review the publication )

Viruses, 2020, 12(10)E1067

PubMed: 32977702 ( click the link to review the publication )
Oncogene, 2020, 10.1038/s41388-020-01408-7

PubMed: 32733069 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01191-y

PubMed: 33250513 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Genes Dev, 2020, 34(5-6):428-445

PubMed: 32001510 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4429-4439

PubMed: 32606937 ( click the link to review the publication )

Biomater Sci, 2020, 10.1039/d0bm00119h

PubMed: 32706009 ( click the link to review the publication )

Cell Cycle, 2020, 1-16

PubMed: 32807015 ( click the link to review the publication )

Life Sci, 2020, 248:117469

PubMed: 32109485 ( click the link to review the publication )

Chin Med J (Engl), 2020, 5;133(11):1304-1311

PubMed: 32452893 ( click the link to review the publication )

Pharmaceuticals (Basel), 2020, 13(11)E345

PubMed: 33121173 ( click the link to review the publication )

Pharm Biol, 2020, 58(1):231-238

PubMed: 32202448 ( click the link to review the publication )

PLoS Biol, 2020, 18(12):e3000941

PubMed: 33264286 ( click the link to review the publication )

PLoS Biol, 2020, 18(11):e3000981

PubMed: 33253182 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

Int J Cancer, 2019, 145(9):2496-2508

PubMed: 30963560 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)E645

PubMed: 31083396 ( click the link to review the publication )
Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):85

PubMed: 31142371 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):4

PubMed: 30642362 ( click the link to review the publication )

Oncologist, 2019, 24(8):e740-e748

PubMed: 30696721 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656155

PubMed: 31423895 ( click the link to review the publication )

Epigenetics, 2019, 14(8):791-803

PubMed: 31088315 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz254

PubMed: 31691806 ( click the link to review the publication )

Pharmacol Res, 2019, 139:524-534

PubMed: 30366100 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

Bone, 2019, 125:112-121

PubMed: 31100533 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(13)

PubMed: 31269745 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )
J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2019, 22(8):523-527

PubMed: 31179497 ( click the link to review the publication )

NMR Biomed, 2019, 32(2):e4044

PubMed: 30561869 ( click the link to review the publication )

Cancer Biol Ther, 2019,

PubMed: 30142009 ( click the link to review the publication )

Stem Cells Dev, 2019, 28(7):438-453

PubMed: 30667343 ( click the link to review the publication )

Chem Biol Interact, 2019, 306:54-61

PubMed: 30958996 ( click the link to review the publication )

Gene Ther, 2019, 26(3-4):75-85

PubMed: 30538307 ( click the link to review the publication )

Cancer Med, 2019, 8(14):6383-6392

PubMed: 31456359 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0218382

PubMed: 31206526 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Exp Hematol, 2019, 72:60-71

PubMed: 30769020 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Alcohol, 2019, 78:79-87

PubMed: 30851364 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3579-3584

PubMed: 31262882 ( click the link to review the publication )

Neoplasma, 2019, 66(1):20-27

PubMed: 30509083 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Thyroid, 2019, 29(5):726-734

PubMed: 30760120 ( click the link to review the publication )

Medicina (Kaunas), 2019, 55(2)

PubMed: 30700046 ( click the link to review the publication )

Adipocyte, 2019, 8(1):292-303

PubMed: 31322450 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1007-1018

PubMed: 30431129 ( click the link to review the publication )

Chin J Dent Res, 2019, 22(4):221-227

PubMed: 31859282 ( click the link to review the publication )
Front Neurol, 2019, 10:893

PubMed: 31481925 ( click the link to review the publication )

Cell Host Microbe, 2018, 24(5):689-702

PubMed: 30344003 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

Haematologica, 2018, 103(4):679-687

PubMed: 29305415 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Acta Biomater, 2018, 71:261-270

PubMed: 29526828 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):153

PubMed: 30012171 ( click the link to review the publication )

PLoS Pathog, 2018, 14(6):e1007061

PubMed: 29879225 ( click the link to review the publication )

Oncoimmunology, 2018,

PubMed: 30377559 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Cancer Sci, 2018, 109(8):2520-2531

PubMed: 29917299 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(5):2600-2611

PubMed: 29461008 ( click the link to review the publication )

Front Pharmacol, 2018, 9:509

PubMed: 29867508 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3875

PubMed: 29497113 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Front Microbiol, 2018, 9:2022

PubMed: 30283406 ( click the link to review the publication )
J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):466

PubMed: 29695239 ( click the link to review the publication )

Biol Sex Differ, 2018, 9(1):12

PubMed: 29530094 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):264-270

PubMed: 29115632 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):481-486

PubMed: 29505792 ( click the link to review the publication )

AAPS PharmSciTech, 2018, 19(2):634-647

PubMed: 28948528 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

JCI Insight, 2018, 3(4)95824

PubMed: 29467324 ( click the link to review the publication )

Sci Adv, 2018, 4(9):eaar4666

PubMed: 30263952 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(1):47-54

PubMed: 27870832 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2017,

PubMed: 28673995 ( click the link to review the publication )

Haematologica, 2017, 102(4):736-745

PubMed: 27979926 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Oncogene, 2017, 36(34):4859-4874

PubMed: 28414307 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )
Br J Pharmacol, 2017, 174(20):3608-3622

PubMed: 28749535 ( click the link to review the publication )

Sci Signal, 2017, 10(508)eaan8355

PubMed: 29208683 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2570

PubMed: 28125090 ( click the link to review the publication )

Cell Death Dis, 2017,

PubMed: 29022919 ( click the link to review the publication )

Mol Ther Oncolytics, 2017,

PubMed: 28812060 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(11):1356-1367.e8

PubMed: 28943357 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

Eur J Med Chem, 2017, 141:596-602

PubMed: 29102179 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1485-1492

PubMed: 28498513 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

Sci Rep, 2017, 7(1):11547

PubMed: 28912522 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

J Biol Chem, 2017, 292(12):5043-5054

PubMed: 28167529 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Pharm Res, 2017, 34(3):668-679

PubMed: 28101809 ( click the link to review the publication )

Cancer Res Treat, 2017, 49(2):374-386

PubMed: 27488871 ( click the link to review the publication )

Cancer Med, 2017, 6(11):2673-2685

PubMed: 29024573 ( click the link to review the publication )

Mol Immunol, 2017, 87:76-85

PubMed: 28412547 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:88-95

PubMed: 28323055 ( click the link to review the publication )

Am J Surg, 2017, 213(4):645-651

PubMed: 28007318 ( click the link to review the publication )
Nucleus, 2017, 8(5):515-533

PubMed: 28696859 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(28):45687-45697

PubMed: 28537899 ( click the link to review the publication )

Oncotarget, 2017, 9(1):512-523

PubMed: 29416632 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

CPT Pharmacometrics Syst Pharmacol, 2017, 6(11):756-764

PubMed: 29045072 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2290

PubMed: 28536458 ( click the link to review the publication )

Oncotarget, 2017, 8(45):78480-78495

PubMed: 29108243 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103797-103814

PubMed: 29262601 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423644 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29371976 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103797-103814

PubMed: 29262601 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Cell Death Differ, 2016, 23(8):1312-21

PubMed: 26915294 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )
Drug Discov Today, 2016, 21(9):1553-1560

PubMed: 27371506 ( click the link to review the publication )

mBio, 2016, 7(6)

PubMed: 27803184 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Oncoimmunology, 2016,

PubMed: 27471639 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2432-2441

PubMed: 27474150 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1364-75

PubMed: 27196750 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(7):521-33

PubMed: 27267120 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(6):2076-92

PubMed: 27067055 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2685-2692

PubMed: 27459069 ( click the link to review the publication )

Neuropharmacology, 2016, 107:111-121

PubMed: 26970016 ( click the link to review the publication )

Biochem Pharmacol, 2016, 102:130-140

PubMed: 26718586 ( click the link to review the publication )

Sci Rep, 2016, 6:38219

PubMed: 27910887 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10131-47

PubMed: 27022024 ( click the link to review the publication )

Neurochem Int, 2016, 96:24-31

PubMed: 27103167 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2016, 311(5):H1139-H1149

PubMed: 27638876 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Anal Bioanal Chem, 2016, 408(13):3547-53

PubMed: 26968571 ( click the link to review the publication )

BMC Cancer, 2016, 16:667

PubMed: 27549189 ( click the link to review the publication )

Biol Chem, 2016,

PubMed: 26431101 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

Med Oncol, 2016, 33(2):11

PubMed: 26732474 ( click the link to review the publication )

Inflammation, 2016, 39(1):39-46

PubMed: 26228975 ( click the link to review the publication )
PLoS One, 2016, 11(8):e0160826

PubMed: 27536989 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0145985

PubMed: 26726879 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(3):692-9

PubMed: 26084206 ( click the link to review the publication )

Asian Pac J Trop Med, 2016, 9(6):572-6

PubMed: 27262069 ( click the link to review the publication )

Oncotarget, 2016, 7(42):68360-68370

PubMed: 27588392 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Oncotarget, 2016, 8(62):104733-104744

PubMed: 29285209 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7390-402

PubMed: 26862729 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26824319 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58142-58147

PubMed: 27494885 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Nat Commun, 2015, 6:7888

PubMed: 26223951 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cancer Res, 2015,

PubMed: 26294211 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Cell Death Differ, 2015, 22(8):1328-40

PubMed: 25591738 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

EBioMedicine, 2015, 3:108-121

PubMed: 26870822 ( click the link to review the publication )
Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:33

PubMed: 25888415 ( click the link to review the publication )

J Neurosci, 2015, 35(33):11729-42

PubMed: 26290249 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1692

PubMed: 25766331 ( click the link to review the publication )

Cell Death Discov, 2015, 115012

PubMed: 26279947 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1657

PubMed: 25695609 ( click the link to review the publication )

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2316-24

PubMed: 26162280 ( click the link to review the publication )

Neuropharmacology, 2015, 99:67-78

PubMed: 26188143 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochem Pharmacol, 2015, 94(2):79-90

PubMed: 25600908 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(7):975-85

PubMed: 25835755 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(3):1829-36

PubMed: 25492871 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Front Mol Neurosci, 2015, 8:52

PubMed: 26441515 ( click the link to review the publication )
BMC Cancer, 2015, 15:343

PubMed: 25929737 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0130339

PubMed: 26091518 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0139740

PubMed: 26466379 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134825

PubMed: 26284517 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143897

PubMed: 26623653 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

J Biomol Screen, 2015, 20(10):1286-93

PubMed: 26384394 ( click the link to review the publication )

Mol Vis, 2015, 21:502-14

PubMed: 25999677 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):4291-4297

PubMed: 26095064 ( click the link to review the publication )

Genes Cancer, 2015, 6(3-4):169-81

PubMed: 26000099 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25801-14

PubMed: 26317649 ( click the link to review the publication )

Circ Heart Fail, 2015, 8(6):1094-104

PubMed: 26371176 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Acta Neuropathol, 2014, 128(2):291-303

PubMed: 24839957 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

Oncogene, 2014, 33(25):3307-15

PubMed: 23995789 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )
PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2014, 14(1):112

PubMed: 25546354 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Virology, 2014, 462-463:328-39

PubMed: 25014309 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(3):305-16

PubMed: 24351423 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5637-50

PubMed: 25026298 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )
Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Methods Mol Biol, 2014, 1156:431-43

PubMed: 24792006 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 14;121(11):2038-50

PubMed: 23327920 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Res, 2013, 73(8):2428-34

PubMed: 23382048 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 160(2):188-98

PubMed: 23167276 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

Apoptosis, 2013, 18(11):1348-1362

PubMed: 23708756 ( click the link to review the publication )

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

PLoS Comput Biol, 2013, 9(2):e1002887

PubMed: 23408876 ( click the link to review the publication )

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )
Front Pharmacol, 2013, 4:44

PubMed: 23596417 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Blood, 2012, 8;120(19):3958-67

PubMed: 22983447 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )

Oncol Rep, 2012, 28(1):105-10

PubMed: 22484732 ( click the link to review the publication )
PLoS One, 2012, 7(7):e40684

PubMed: 22808232 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )

Biochem Biophys Res Commun, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )

Mol Med, 2011, 17(5-6):466-72

PubMed: 21424110 ( click the link to review the publication )

PLoS One, 2011, 6(6):e21382

PubMed: 21738649 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )

BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683)是一种HDAC抑制剂，无细胞试验中IC50为~10 nM。Vorinostat 会抑制高效的HPV-18 DNA扩增。

特性

Vorinostat是广谱HDAC活性抑制剂，抑制I和II类酶。

靶点

HDAC ^[1]
(Cell-free assay)

~10 nM

体外研究

Vorinostat是小分子量（<300）线性肟酸，抑制HDAC活性，包括乙酰化组蛋白和非组蛋白的积累，抑制培养细胞的增殖，且抑制肿瘤生长。Vorinostat通过结合到酶的活性位点而抑制 HDAC活性。Vorinostat 抑制多种转化细胞增殖（包括淋巴瘤，多发性骨髓瘤，白血病，和非小细胞肺癌），与对照组相比抑制生长达50% 时的浓度为0.5 到10μM。Vorinostat作用于淋巴瘤和白血病细胞，包括 Burkitt, B-细胞急性淋巴细胞白血病 (B-ALL), MCL, DLBCL, ATL和T-细胞，不同程度抑制细胞增殖。除了抑制转化细胞增殖, Vorinostat 也抑制正常细胞增殖，通过比较Vorinostat 作用于一组细胞系–正常人非纤维细胞(WI-38)和 SV40巨大T抗原转化WI-38(VA-13细胞)而得到证明。Vorinostat 抑制两种类型细胞增殖，这种作用存在剂量依赖性。但发现Vorinostat 对转化细胞具有选择毒性，包括使肿瘤细胞死亡，而对正常细胞只起抑制作用，不会使其死亡。^[1] Genistein 和Vorinostat 联用效果比5-aza和Vorinostat 联用作用于诱导细胞死亡有效很多。Genistein和Vorinostat联用作用于ARCaP-E使增殖降低 80 %，作用于ARCaP-M细胞，增殖降低60 %以上。Genistein和Vorinostat 联用抑制细胞增殖具有协同效应。作用于ARCaP-E 细胞(820个基因诱导和1046个基因抑制) ARCaP-M 细胞，Vorinostat比Genistein 影响更多基因。^[2] Vorinostat作用于肿瘤细胞表面，提高Fas蛋白水平，这种作用存在剂量依赖性，且按0.75 μM剂量处理，提高达到一个稳定水平。^[3] Vorinostat 抑制肿瘤细胞生长，包括NB4, H460 和HCT-116，IC50分别为0.7μM, 3.4μM和1.2 μM。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
H1299	MYHLbY5ie2ViQYPzZZk>		NV3jSmxpOjBibXnu	NXrlOJVGTE2VTx?=	MkLqTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGhFSUNiZX76fY1mKHerdHigTWM2OCCxZjCwMlE6PCEQvF2=	NWKwPG0yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1NlE1OjJpPkG0OVIyPDJ{PD;hQi=>
HT1080	MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2CwNlczKGh?	MkXmSG1UVw>?	MWPJR\|UxRTJwNDFOwG0>	NYP2OHZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKyO\|AyPzVpPkGyNlcxOTd3PD;hQi=>
K562	NGGwfY9McW6jc3WgRZN{[Xl?		M{Gw[lYhcA>?	NULyOoxrTE2VTx?=	MYXJcohq[mm2aX;uJI9nKGi3bXHuJIhqe3SxbnWg[IVi[2W2eXzhd4UhMG2reIT1doUhd2ZiSFTBR\|Eh[W6mIFjERWMzMSC5aYToJGlEPTBib3[gNE4xOSEQvF2=	MnjqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ2MUmzPFAoRjF{NEG5N\|gxRC:jPh?=
A20	NFjNU2dMcW6jc3WgRZN{[Xl?		NWnNfoNIOSCq	NWrRT2JnTE2VTx?=	NGPxenBidnSrLVjERWMyKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEyOiEQvF2=	NIrzVpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUm2NFQ5QSd-MUG5OlA1QDl:L3G+
Friend leukemic cell	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nwSVUxKM7:TR?=	MX63NkBp	NFHyeVFFVVOR	MnnyTWM2OD1yLkm5JO69VQ>?	NYLoSGM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxNFk6OTNpPkGyNVA6QTF\|PD;hQi=>
H1299	MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2XTVlczKGh?	MXXEUXNQ	NVPrc3RkUUN3ME23MlI1KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV{MUSyNkc,OTR3MkG0NlI9N2F-
HeLa	MULLbY5ie2ViQYPzZZk>		NEHOfJE{OCCvaX6=		NIjISWtKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6\|dDDobZN1d26nIHTlZYNmfHmuYYPlJJdqfGhiSVO1NEBw\iByLkK4JO69VQ>?	M4DPeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkCzPVQ6Lz5zNU[wN\|k1QTxxYU6=
LOX-IMVI	M2DRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnH0OFghcA>?		NFzadY1KSzVyPUGuN{DPxE1?	M1;mSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3N{G1OFcxLz5zNUexOVQ4ODxxYU6=
NCI-H226	M1TPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MY[0PEBp		NVvsOIFMUUN3ME2yMlYh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTdzNUS3NEc,OTV5MUW0O\|A9N2F-
RXF-631L	M1e3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXPwdHhpPDhiaB?=		NHrLVoJKSzVyPUKg{txO	MmnCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV5MUW0O\|AoRjF3N{G1OFcxRC:jPh?=
SNB-78	M4XJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1jqR\|Q5KGh?		MkjsTWM2OD1zNjFOwG0>	MmPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV5MUW0O\|AoRjF3N{G1OFcxRC:jPh?=
St-4	NUnWSnVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIf6[VA1QCCq		NXixVFBlUUN3ME21MlIh\|ryP	M3j4PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3N{G1OFcxLz5zNUexOVQ4ODxxYU6=
ARP1	NVfRTpRQTnWwY4Tpc44hSXO\|YYm=	NV7ZbYhWOiEQvF2=	NIHqVVU3KGh?		MoLPTY5lfWO2aX;uJI9nKFB{MWfBSlEh\2WwZTDlfJBz\XO\|aX;u	NVP2NoR3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS3N\|Q5ODZpPkG0O\|M1QDB4PD;hQi=>
CEM	M3TCdmtqdmG\|ZTDBd5NigQ>?		M4THV\|EhcA>?	NUT4V5JUTE2VTx?=	M1W4R2lvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1?	NV3vV\|RORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NlAxPjRpPkG2OFIxODZ2PD;hQi=>
HCT15	M2TJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVW0PEBp		NV7GRYdnT0l3ME2wMlgzKM7:TR?=	MorhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5MkOyNlcoRjF4N{KzNlI4RC:jPh?=
NCI-H23	M1\6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXe0PEBp		M2rqNWdKPTB;MD65NkDPxE1?	NW\oN2VvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3NlMzOjdpPkG2O\|I{OjJ5PD;hQi=>
GM15850	MnL2T4lv[XOnIFHzd4F6	MVOyMlUh\|ryP	NYL3SXA{QTZiaB?=	M1K4bWROW09?	NHPQOnFKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgNVQh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M37Y[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
GM15850	MVzLbY5ie2ViQYPzZZk>	M1[2TFIvPSEQvF2=	MlL3PVYhcA>?	MX;EUXNQ	MlLmTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEWgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	M3KyflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
GM15850	M3nKZ2tqdmG\|ZTDBd5NigQ>?	NGnaTYEzNjVizszN	Mkn5PVYhcA>?	NIHoZ2lFVVOR	MmXNTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEGyJIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	MkXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MkGzOlcoRjF4OUKxN\|Y4RC:jPh?=
GM15850	MUjLbY5ie2ViQYPzZZk>	M{jMb\|IvPSEQvF2=	NWrTTFA5QTZiaB?=	NUnUO2Z[TE2VTx?=	NVfRT2NXUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M2\Db\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
GM15850	NE\HOpdMcW6jc3WgRZN{[Xl?	NEX0fnQzNjVizszN	MXO5OkBp	NFHwbnZFVVOR	NILQNFhKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgPEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	M2S5NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
GM15850	NULGdW9FU2mwYYPlJGF{e2G7	MYKyMlUh\|ryP	MX[5OkBp	M2HLU2ROW09?	M3roNmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTCxOkBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	M4T2OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
U937	NUTkUpBTTnWwY4Tpc44hSXO\|YYm=	NYHEUYlpPSEQvF2=	NWnxZpVHOjRiaB?=	M4jtcGROW09?	MnPmR4VtdCCleXPs[UBienKnc4SgZpkh[WOldX31cIF1cW:wIHH0JHMwTzJxTTDwbIF{\Q>?	MmnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyMES3NVgoRjF5MEC0O\|E5RC:jPh?=
H661	M4i2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV3GU2NqPDhiaB?=		MnfBTWM2OD1zIN88US=>	NGXPPGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{G1O\|AxQSd-MUexOVcxODl:L3G+
U937	M4n0W2Z2dmO2aX;uJGF{e2G7	MXu1JO69VQ>?	MoH6NlQhcA>?	MnzwSG1UVw>?	NXXBeWxmUW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=>	M3XoSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NES3O\|UxLz5zN{S0O\|c2ODxxYU6=
U937	MUXGeY5kfGmxbjDBd5NigQ>?	M4f0SlEh\|ryP	NWDNV4NxOjRiaB?=	NG\ISo1FVVOR	MXXF[oZm[3Rib36gZYxxcGFidIXieYxqdiCjY3X0fYxifGmxbh?=	NXnLfnpZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0OFc4PTBpPkG3OFQ4PzVyPD;hQi=>
RAW264.7	MUnGeY5kfGmxbjDBd5NigQ>?	M{nRXVExKM7:TR?=	Ml\sNlRp	Mn3Ve4F1\XJ?	M{mwZWlvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhXE6IYXzwbIEheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE44PiEQvF2=	Mnf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2N{e1NVgoRjF5NEe3OVE5RC:jPh?=
RAW264.7	M3;uZ2Z2dmO2aX;uJGF{e2G7	NVLF[XIxOTBizszN	NHX2XFEzPGh?	M1z3fpdifGW{	MlSyTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBPVyCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAyNjh6IN88US=>	NUjCcmpJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0O\|c2OThpPkG3OFc4PTF6PD;hQi=>
SC9	M2HQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn33OFghcA>?		MWPJR\|UxRTBwNkC2JO69VQ>?	M4XJSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUC3NlE6Lz5zN{WwO\|IyQTxxYU6=
ST14A	MYfGeY5kfGmxbjDBd5NigQ>?	M1PxRlUhdk1?	M3j0XVczKGh?		MlrPTY5kemWjc3WgbY4hWkWVVD;OVnNHKG2UTlGg[ZhxemW\|c3nvci=>	MnXiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NkW5PVMoRjF5NU[1PVk{RC:jPh?=
ST14A	NX;TUJk6TnWwY4Tpc44hSXO\|YYm=	MlPnOUBvVQ>?	NGD4TXk4OiCq		MYLJcoNz\WG\|ZTDpckBGOkZzIH3SUmEh\XiycnXzd4lwdg>?	NUXBNlRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OlU6QTNpPkG3OVY2QTl\|PD;hQi=>
PANC1	NHnnNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmT3NUDPxE1?			MYHJR\|UxRTBwNEWg{txO	M17oVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUi4O\|Q1Lz5zN{W4PFc1PDxxYU6=
PANC1	M{G0S2Z2dmO2aX;uJGF{e2G7	NWXLWYs5OSEQvF2=	NU\ye4JuOjRiaB?=		NYrDZoJkUW6lcnXhd4UhcW5icEKxW2FHOS:FSWCxJIdmdmViZYjwdoV{e2mxbh?=	NFH5ZW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W4PFc1PCd-MUe1PFg4PDR:L3G+
PANC1	MnjQSpVv[3Srb36gRZN{[Xl?	NEHBfJgyKM7:TR?=	NInnfYUzPCCq		NYnJcYZtUW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV6OEe0OEc,OTd3OEi3OFQ9N2F-
PT45	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTRizszN	NIL6OI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W4PFc1PCd-MUe1PFg4PDR:L3G+
ACHN	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYqyNUBp		M{jHdWdKPTB;MD62OUDPxE1?	NUDa[25iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2OlI3ODZpPkG3OlYzPjB4PD;hQi=>
PC3	NWXzWJJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXLZSnNGOjFiaB?=		M4fidWdKPTB;MD63NUDPxE1?	NEnXUng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[2NlYxPid-MUe2OlI3ODZ:L3G+
A431	NHj4flZEgXSxdH;4bYMhSXO\|YYm=		NYfpWm1IPzJiaB?=		MX;JR\|UxRTRwMjFOwG0>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ7MUe2N{c,OTd4OUG3OlM9N2F-
Cal27	NILjfG5EgXSxdH;4bYMhSXO\|YYm=		MW[3NkBp		M37NPWlEPTB;Mz6yJO69VQ>?	Mm\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4OUG3OlMoRjF5NkmxO\|Y{RC:jPh?=
CCRF-CEM	MVPDfZRwfG:6aXOgRZN{[Xl?		NVK2NpY5PzJiaB?=		MUPJR\|UxRTBwODFOwG0>	NEHY[II9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[5NVc3Oyd-MUe2PVE4PjN:L3G+
EOL1	M3nKfWN6fG:2b4jpZ{BCe3OjeR?=		NEfPNVg4OiCq		NX;KcnJTUUN3ME2xJO69VQ>?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ7MUe2N{c,OTd4OUG3OlM9N2F-
Hec-1-A	MYDDfZRwfG:6aXOgRZN{[Xl?		MnnCO\|IhcA>?		NIPU[G9KSzVyPUGg{txO	NVTzN4plRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2PVE4PjNpPkG3OlkyPzZ\|PD;hQi=>
HeLa	M2rGPWtqdmG\|ZTDBd5NigQ>?	MmHMNVAh\|ryP	NWj6ZWxPOzBibXnu	MXzEUXNQ	NYKzS3JjUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBJTEGFMTD3bZRpKEmFNUCgc4YhOC5yMjFOwG0>	NYfHTYtMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2PVE4PjNpPkG3OlkyPzZ\|PD;hQi=>
RKOp21	Mlz3R5l1d3SxeHnjJGF{e2G7		MW[3NkBp		NYfQSGdWUUN3ME2xMlc3KM7:TR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ7MUe2N{c,OTd4OUG3OlM9N2F-
Saos2	NF\LbYdEgXSxdH;4bYMhSXO\|YYm=		NHu2XXc4OiCq		MmnpTWM2OD1{LkOg{txO	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ7MUe2N{c,OTd4OUG3OlM9N2F-
SK-OV-3	MkfER5l1d3SxeHnjJGF{e2G7		MYG3NkBp		NIDBUHpKSzVyPUKuNkDPxE1?	M1\MTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkmxO\|Y{Lz5zN{[5NVc3OzxxYU6=
U87MG	M1zmNGN6fG:2b4jpZ{BCe3OjeR?=		NVf2bIVmPzJiaB?=		NE\NdoJKSzVyPUGxJO69VQ>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ7MUe2N{c,OTd4OUG3OlM9N2F-
NUGC3	NVvkSlFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWG1JO69VQ>?	MVWyOEBp		MVrHTVUxRTJwN{mg{txO	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzlyNEi0N{c,OTd7MES4OFM9N2F-
CCD1059SK	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{m1U2lEPTB;NEOuOUDPxE1?	MmnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OVQoRjF6MkS3OVU1RC:jPh?=
HepG2	MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfWTG81UUN3ME2wMlAxODZizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
HT1080	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTBwMECyOEDPxE1?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
SKBR3	NELxOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1r6TWlEPTB;MD64JO69VQ>?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
SNB78	M4DMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInuUZhGSzVyPUG2JO69VQ>?	MlvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OVQoRjF6MkS3OVU1RC:jPh?=
SQ20B	NVXtVJVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDBTWM2OD1\|IN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
St4	Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PFVGVEPTB;NT6yJO69VQ>?	NV\ZbZF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
MCF7	MUfGeY5kfGmxbjDBd5NigQ>?	NHnvNo8yOCEQvF2=	NVXUTI5bQCCq	MoW1SG1UVw>?	MlrkTY5lfWO2aX;uJI9nKHS3YoXsbY4hcHmyZYLhZ4V1gWyjdHnvci=>	NWfCXod[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOlkzOjZpPkG4NlY6OjJ4PD;hQi=>
HEK293	MYTLbY5ie2ViQYPzZZk>		NXnuc2VCOSCq	NWX0bWQyTE2VTx?=	NFrCWIRKdmirYnn0bY9vKG:oIFjERWMyKHerdHigTWM2OCCxZjCwMlA{KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDNyOEW2N{c,OTh\|MEi1OlM9N2F-
HEK293	MV3LbY5ie2ViQYPzZZk>		NU\JTWduOSCq	MVnEUXNQ	NWnUTlBXUW6qaXLpeIlwdiCxZjDISGFEOyC5aYToJGlEPTBib3[gNE4xPTdizszN	NUHGO\|RnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNFg2PjNpPkG4N\|A5PTZ\|PD;hQi=>
G401	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3f0SVczKGh?	M3npZWROW09?	MULJR\|UxRTFizszN	NITFOFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO3NFM4Oyd-MUizO\|A{PzN:L3G+
HeLa	M1vmRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWr1VJlEPzJiaB?=	M2K1XWROW09?	MW\JR\|UxRTBwNE[g{txO	NV60Z\|ZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO\|A{PzNpPkG4N\|cxOzd\|PD;hQi=>
Human renal epithelial cell	M375WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlzXO\|IhcA>?	MW\EUXNQ	NG\FOIpKSzVyPUG0JO69VQ>?	MmrBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|N{CzO\|MoRjF6M{ewN\|c{RC:jPh?=
U937	NY[zT4llTnWwY4Tpc44hSXO\|YYm=	NU\4TW1pPSEQvF2=	NYXpNJpIOjRiaB?=		MkX5TY5lfWO2aX;uJI9nKGirc4TvcoUhUDRiaInw[ZJi[2W2eXzheIlwdg>?	M1PlTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{ixNlM5Lz5zOEO4NVI{QDxxYU6=
U937	MVLGeY5kfGmxbjDBd5NigQ>?	M172NVUh\|ryP	M3[zfFI1KGh?		MnvMTY5lfWO2aX;uJI9nKGGucHjhJJR2[nWuaX6gbJlx\XKjY3X0fYxifGmxbh?=	M3T4V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{ixNlM5Lz5zOEO4NVI{QDxxYU6=
U937	NXSxVXVNTnWwY4Tpc44hSXO\|YYm=	MWS1JO69VQ>?	Mo\hNlQhcA>?		MXTJcoR2[3Srb36gc4YheDJzIHX4dJJme3Orb36=	M3n2WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{ixNlM5Lz5zOEO4NVI{QDxxYU6=
U937	M4rEe2Z2dmO2aX;uJGF{e2G7	NH;IfFc2KM7:TR?=	Mn\BNlQhcA>?		MWnJcoR2[3Srb36gc4Yh[XCxcITvd4l{	NWO1[ZV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizPFEzOzhpPkG4N\|gyOjN6PD;hQi=>
U937	NHTFb2pHfW6ldHnvckBCe3OjeR?=	M4Hoc\|Uh\|ryP	NYHPVGRDOjRiaB?=		NGPvWIFKdmS3Y4Tpc44hd2ZiZ4LhcpVtd2O7dHnjJIRq\m[ncnXueIlifGmxbh?=	NH7GU4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO4NVI{QCd-MUizPFEzOzh:L3G+
U937	MVvLbY5ie2ViQYPzZZk>	NWH4Z\|BvPSEQvF2=	NUTGRXpjOjRiaB?=		NX6yVnBGUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDNS=>	M{XhU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{ixNlM5Lz5zOEO4NVI{QDxxYU6=
U937	MlfCT4lv[XOnIFHzd4F6	M3HTRlUh\|ryP	NEK1eWYzPCCq		NYi2bYlCUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDOC=>	NE\kXG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO4NVI{QCd-MUizPFEzOzh:L3G+
HEK-TE	NFjYd4lHfW6ldHnvckBCe3OjeR?=	NGTVS5E2KM7:TR?=	MlvpOog>	NYrXWoJETE2VTx?=	NVrSVJB4UW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=>	Mn:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2M{SxOFQoRjF6NEO0NVQ1RC:jPh?=
HPDE6c7	MlLXR5l1d3SxeHnjJGF{e2G7	MWm1NEDPxE1?	MXK3NkBp	M1zQWGROW09?	Mo\UTWM2OD1zLkOg{txO	MlW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2OUS0OlMoRjF6NEm0OFY{RC:jPh?=
Human microvascular epithelial cell	NHrSN2hEgXSxdH;4bYMhSXO\|YYm=	NX36fIRFPTBizszN	M3\SWlczKGh?	NFPzRXBFVVOR	NYfkPXRxUUN3ME2xMlMh\|ryP	M3\jbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEm0OFY{Lz5zOES5OFQ3OzxxYU6=
Hup T3	NYTr[JhlS3m2b4TvfIlkKEG\|c3H5	MonLOVAh\|ryP	NEDre5M4Omh?	Ml3ZSG1UVw>?	NYLROpJ1UUN3ME2wMlgh\|ryP	M2LoPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEm0OFY{Lz5zOES5OFQ3OzxxYU6=
Mia Paca2	M4fqTGN6fG:2b4jpZ{BCe3OjeR?=	NYTBXIVHPTBizszN	M3TE[VczcA>?	NILFcINFVVOR	MVvJR\|UxRTFwMTFOwG0>	NUC5N\|R6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0PVQ1PjNpPkG4OFk1PDZ\|PD;hQi=>
Panc 04.03	Mnv2R5l1d3SxeHnjJGF{e2G7	NXXiRlMxPTBizszN	M2DrdFczcA>?	Mn\1SG1UVw>?	M{Ph[2lEPTB;MT6yJO69VQ>?	MmW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2OUS0OlMoRjF6NEm0OFY{RC:jPh?=
SU 86.86	NHvRN2REgXSxdH;4bYMhSXO\|YYm=	NUDwfog4PTBizszN	M2ToN\|czcA>?	MlewSG1UVw>?	MXjJR\|UxRTFwMzFOwG0>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR7NES2N{c,OTh2OUS0OlM9N2F-
HEK293	MWDLbY5ie2ViQYPzZZk>		MWqzJIg>		MVLJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjERWM3KGW6cILld5Nqd25id3n0bEBKSzVyIH;mJFAvODF7IN88US=>	NU[2fnRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OVg3PjlpPkG4OVU5PjZ7PD;hQi=>
HeLa	M2j5PWtqdmG\|ZTDBd5NigQ>?		NIX1cGkzKGh?		M4TXRWlvcGmkaYTpc44hd2ZiboXjcIVieiCKRFHDJJdqfGhiSVO1NEBw\iByLkC4N{DPxE1?	MlPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUi2OlkoRjF6NUW4OlY6RC:jPh?=
RAW264.7	NFHZ[mRHfW6ldHnvckBCe3OjeR?=	NVfkcmFiOiEQvF2=	NEX6e3Y{NjViaB?=	M4LqUWROW09?	MYrBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iaX7m[YN1\WRid3n0bEBKSzVyIH;mJFAvOTFizszN	NFG2b5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[0OFk3QSd-MUi2OFQ6Pjl:L3G+
NB4			M{D0eVQ5cA>?	MYDEUXNQ	NHnpXllKSzVyPUCuOkDPxE1?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd{M{O0PUc,OTh5MkOzOFk9N2F-
HEK293	NF2z[5ZHfW6ldHnvckBCe3OjeR?=	NFHTVJcyOCEQvF2=	MVWyOEBp	NEjPNHdFVVOR	MmjORYN1cX[jdHnvckBw\iCvb4Xz[UBYdnR\|YTDzbYdv[Wyrbneg[ZhxemW\|c3Xk	NIHrUYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCyNlY4PSd-MUmwNlI3PzV:L3G+
HCT116	Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NY[yXHVmPzKq	NUnseYpKTE2VTx?=	Ml\jTWM2OD1yLkOxJO69VQ>?	NYfhV4dzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwPFQzQTRpPkG5NFg1Ojl2PD;hQi=>
HeLa	MnXWT4lv[XOnIFHzd4F6	M1zsclIh\|ryP	NGW0XWs{OCCvaX6=	M3LSNGROW09?	NF3INVRKdmirYnn0bY9vKG:oIFjERWMzKGmwIHj1cYFvKEinTHGgZ4VtdHNid3n0bEBKSzVyIH;mJFAvOSEQvF2=	M1z2N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEi0Nlk1Lz5zOUC4OFI6PDxxYU6=
IGROV1	M{Hy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIDsfoE4OiCq	M1TtdGROW09?	Mn3ZTWM2OD1{LkKg{txO	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB6NEK5OEc,OTlyOESyPVQ9N2F-
IGROV1	MnnKT4lv[XOnIFHzd4F6	NFvIRY82KM7:TR?=	M{nVcFI1KGh?	MoewSG1UVw>?	NHPueYdKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNicEWzJIFk\XS7bHH0bY9v	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB6NEK5OEc,OTlyOESyPVQ9N2F-
IGROV1	NEjsXYtMcW6jc3WgRZN{[Xl?	NFHwepkyOCEQvF2=	MlP2OEBp	M3:2[mROW09?	NH3nbIpKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaHnzeI9v\S2KNDDhZ4V1gWyjdHnvci=>	NIjBZ2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC4OFI6PCd-MUmwPFQzQTR:L3G+
IGROV1	MnfsT4lv[XOnIFHzd4F6	NXjpXmt5OTBizszN	MWe0JIg>	NGHpdIhFVVOR	M2jIfWlvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiYXzwbIEufHWkdXzpckBi[2W2eXzheIlwdg>?	NFvyd4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC4OFI6PCd-MUmwPFQzQTR:L3G+
T24	M{K1UWtqdmG\|ZTDBd5NigQ>?		NGTrZXA{KGh?		MUfJcoR2[3Srb36gc4YhcGm\|dH;u[UBJOyCjY3X0fYxifGmxbjD3bZRpKEWFNUCgc4YhOC5zMjFOwG0>	NUfVT5BwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwPFQ{QTVpPkG5NFg1Ozl3PD;hQi=>
T24	MWjLbY5ie2ViQYPzZZk>		M{nNcFMhcA>?		NXjzfHdxUW6mdXP0bY9vKG:oIHHsdIhiKHS3YoXsbY4h[WOndInsZZRqd25id3n0bEBGSzVyIH;mJFAvOjVizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB6NEO5OUc,OTlyOESzPVU9N2F-
HeLa	MV\LbY5ie2ViQYPzZZk>		NFzmWoEyPSCvaX6=	MkT5SG1UVw>?	MXLJcohq[mm2aX;uJI9nKEiGQVO2JIZzd21iboXjcIVieiCneITyZYN1KHerdHigTWM2OCCxZjCwMlA5PTVizszN	NIHkVZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC5N\|g5PCd-MUmwPVM5QDR:L3G+
HeLa	NFLUbIdMcW6jc3WgRZN{[Xl?		M4jrPFE2KG2rbh?=	MX;EUXNQ	M3zhVmlvcGmkaYTpc44hd2ZiSFTBR\|gh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFEvQDZizszN	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB7M{i4OEc,OTlyOUO4PFQ9N2F-
NCI-H69	MUnDfZRwfG:6aXOgRZN{[Xl?		MWi3NkBp	M{DwN2ROW09?	NHnNem1KSzVyPUKuNFYh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB7M{i4OEc,OTlyOUO4PFQ9N2F-
SKMES1	MWnDfZRwfG:6aXOgRZN{[Xl?		MojhO\|IhcA>?	NHewe5lFVVOR	M1fJRmlEPTB;Mj60NkDPxE1?	M{jsNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEmzPFg1Lz5zOUC5N\|g5PDxxYU6=
S2	NXzrRoZQU2mwYYPlJGF{e2G7	MmPkNE4yNTFyIN88US=>	M3vQTVEhcA>?		NVWyclM3UW6qaXLpeIlwdiCxZjDQcIF{dW:maYXtJIZidGOrcHHyeY0hUESDQ{Gg[ZhxemW\|c3XkJJdqfGhiSVO1NEBw\iByLkC1PUDPxE1?	M{HyNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{G3OFUxLz5zOUOxO\|Q2ODxxYU6=
SHSY5Y	MXTLbY5ie2ViQYPzZZk>	M4DZS\|ExKM7:TR?=	MWG0PEBp	NYqwTo9uTE2VTx?=	MnTUTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkWg{txO	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTN2NEG3OUc,OTl\|NESxO\|U9N2F-
SHSY5Y	NWPWZ3JTS3m2b4TvfIlkKEG\|c3H5	NEL1fYQyOCEQvF2=	M2PwOVQ5KGh?	MYrEUXNQ	M4nUeWlEPTB;MjFOwG0>	NELze2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUO0OFE4PSd-MUmzOFQyPzV:L3G+
DMS114	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWG0PEBp		NEKxbnlIUTVyPUKuPUDPxE1?	M4GySFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEG5NlA2Lz5zOUSxPVIxPTxxYU6=
HBC5	M2X3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH\VNHI1QCCq		MWDHTVUxRTF5IN88US=>	M3vBb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEG5NlA2Lz5zOUSxPVIxPTxxYU6=
SNB78	MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1nvXFQ5KGh?		M{P5W2dKPTB;MU[g{txO	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTRzOUKwOUc,OTl2MUmyNFU9N2F-
HeLa	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{LCUFczKGh?	MUjEUXNQ	NWq1clJtUUN3ME2wMlQ3KM7:TR?=	NWnvWos6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OFE5PDZpPkG5OFQyQDR4PD;hQi=>
BHK	NFfBUlNMcW6jc3WgRZN{[Xl?	NIfXWWE2KM7:TR?=	MnW4NlQhcA>?	NUO1d\|RFTE2VTx?=	MoLETY5pcWKrdHnvckBw\iCKRFHDO{BmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gdIxie22jIH3lcYJz[W6nIF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4>	M17Kd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[2O\|g6Lz5zOUm2Olc5QTxxYU6=
CFBE41o-	M{PBb2tqdmG\|ZTDBd5NigQ>?	MX[1JO69VQ>?	NFLnN4I5KGh?	MojlSG1UVw>?	MnTkTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGi7cHXyZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SCKMx?=	MoD4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Nk[3PFkoRjF7OU[2O\|g6RC:jPh?=
CFBE41o-	NV3HXmtHU2mwYYPlJGF{e2G7	NXzpR2lXPSEQvF2=	NXyzZ5RnPCCq	NGPSTndFVVOR	NEHFeo5KdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4hdGW4ZXy=	M4DQbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[2O\|g6Lz5zOUm2Olc5QTxxYU6=
CFBE41o-	M1nzVGtqdmG\|ZTDBd5NigQ>?	NV3GW2NXOSEQvF2=	NYL6colkOSCq	M123OmROW09?	MXTJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iQ1\UVkBxem:2ZXnuJIxmfmWu	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl4Nke4PUc,OTl7Nk[3PFk9N2F-
Primary bronchial epithelial cell	NUXLNnhQU2mwYYPlJGF{e2G7	NXPRW4RwOSEQvF2=	M1T3TVI1KGh?	NWD4XJhjTE2VTx?=	NY[weVl[UW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhdXW2YX70JGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5iYYDpZ4FtKHO3cn\hZ4UhdG:lYXzpfoF1cW:w	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl4Nke4PUc,OTl7Nk[3PFk9N2F-
CFBE41o-	MYHLbY5ie2ViQYPzZZk>	MWmxJO69VQ>?	NVW5UFBpPSCmYYnz	NXm5WFdKTE2VTx?=	MVPJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIP0ZYJqdGm8YYTpc44hd2ZiRnTlcJRiPTB6IFPGWHIheHKxdHXpci=>	NXvNPG1XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OlY4QDlpPkG5PVY3Pzh7PD;hQi=>
CFBE41o-	MnrZT4lv[XOnIFHzd4F6	NXHDfGRWOSEQvF2=	NViyeGJROjRiaB?=	MXXEUXNQ	NWLkWmlEUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBH\GWudHG1NFghS0[WUjDwdo91\WmwIITyZYZncWOtaX7n	NUnVSIpmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OlY4QDlpPkG5PVY3Pzh7PD;hQi=>
CFBE41o-	MYDLbY5ie2ViQYPzZZk>	M3rLWlUh\|ryP	M37Ue\|I1KGh?	MmfPSG1UVw>?	M1m2fmlvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gdoF1\SCxZjDtZZR2emG2aX;uJI9nKEOIVGKgdJJwfGWrbjD0c{BqfHNiZ3z5Z49nd3Kv	MkjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Nk[3PFkoRjF7OU[2O\|g6RC:jPh?=
CFBE41o-	NXXGc\|dOU2mwYYPlJGF{e2G7	MmToOUDPxE1?	M1PTW\|I1KGh?	M4HwbWROW09?	NVe1SVV[UW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB{fGGkaXzpeJkhd2ZiRnTlcJRiPTB6IFPGWHIheHKxdHXpci=>	NUDYW4FiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OlY4QDlpPkG5PVY3Pzh7PD;hQi=>
CFBE41o-	NF7PcXBMcW6jc3WgRZN{[Xl?	NYq5dGZuPSEQvF2=	NX3TZolWOjRiaB?=	MoL6SG1UVw>?	MVPJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGOxcoLlZ5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHS{YX\mbYNscW6pIITvJINmdGxic4Xy[oFk\SCjczDncJlkd2[xcn2=	NInv[FM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2Olc5QSd-MUm5OlY4QDl:L3G+
Primary bronchial epithelial cell	M1rK[GtqdmG\|ZTDBd5NigQ>?	MXy1JO69VQ>?	MUCyOEBp	MoHJSG1UVw>?	MnfxTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDteZRidnRiRnTlcJRiPTB6IFPGWHIheHKxdHXpckBieGmlYXygd5Vz\mGlZTDsc4NidGm8YYTpc44>	M17SdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[2O\|g6Lz5zOUm2Olc5QTxxYU6=
Primary bronchial epithelial cell	NID5WG5McW6jc3WgRZN{[Xl?	MX[xJO69VQ>?	MmfOPVYhcA>?	NVXybWloTE2VTx?=	NHnOOmVKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJNpd3K2IHPpdoN2cXRiY4XydoVvfHN?	NWTLXGF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OlY4QDlpPkG5PVY3Pzh7PD;hQi=>
BxPC3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYe3NkBp		MX;JR\|UxRTJwNzFOwG0>	NXP4VYZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
CAL27	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1;ybVczKGh?		NYDuUFVVUUN3ME2zMlczKM7:TR?=	NIS5bmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
Capan1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXW5VFJoPzJiaB?=		MmHVTWM2OD15LkOg{txO	MnHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
HCC827	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{fpSVczKGh?		MmHiTWM2OD1zLkig{txO	NEWxWIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
LNCAP	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4n3XFczKGh?		NGTqZ3VKSzVyPUCuOVgh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
NCI-H2122	NYX0WHc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH\rNWQ4OiCq		MXvJR\|UxRTdwNTFOwG0>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
NCI-H358	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGjGTGw4OiCq		MWrJR\|UxRTJwNTFOwG0>	NXi1c5RxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
SCC15	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEPxNFY4OiCq		M2juemlEPTB;Mj60PUDPxE1?	NVrUT\|NMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
SCC25	NYjyRWRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoLxO\|IhcA>?		MVvJR\|UxRTFwOUOg{txO	MoTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
SKHEP1	MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MY[3NkBp		MWfJR\|UxRTNwNE[g{txO	M{\TdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
BJ	NXm5UoEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXKxNFAh\|ryP	NYm5dXBHPDhiaB?=	M2\Q[2ROW09?	MVrHdo94fGhiaX7obYJqfGmxbjDheEAxNjB3IITvJFExOCC3TR?=	MoXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO4OFAoRjJyMUSzPFQxRC:jPh?=
MUF	NUft[nllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHZVVMyODBizszN	NV7GNIV4PDhiaB?=	MX;EUXNQ	NWnWbHczT3Kxd4ToJIlvcGmkaYTpc44h[XRiMD6wOUB1dyBzMECgeW0>	NXXxdFUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM5PDBpPkKwNVQ{QDRyPD;hQi=>
Caco-2	NE\UXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYSxNFAh\|ryP	NWXBSZR[PDiq	MkG3SG1UVw>?	MonnTWM2OD16LkGg{txO	NH\1V4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|g1OCd-MkCxOFM5PDB:L3G+
Caco-2	NGrUelZMcW6jc3WgRZN{[Xl?	NYqxd\|dDPSEQvF2=	M4qyelQhcA>?	MXjEUXNQ	MnnHTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDhZ4V1gWyjdHnvckBKSzVyIH;mJFAvODN5IN88US=>	NXvJOWZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM5PDBpPkKwNVQ{QDRyPD;hQi=>
Caco-2	Ml\PT4lv[XOnIFHzd4F6	M4rOc\|AvOzF4IH7NJJRwKDNzLk[g{txO	M{G0Z\|QhcA>?	M2fEWmROW09?	NEPYXHJGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Gge4l1cCCLQ{WwJI9nKDBwMUG5JO69VQ>?	NFnlSHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|g1OCd-MkCxOFM5PDB:L3G+
Caco-2	NUCwWYRuU2mwYYPlJGF{e2G7	MkjaNE4{OTZibl2geI8hOzFwNjFOwG0>	NVLMOo9WPCCq	NXHGfY0yTE2VTx?=	NHT1bHBGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Oge4l1cCCLQ{WwJI9nKDBwMUS3JO69VQ>?	NETVNXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|g1OCd-MkCxOFM5PDB:L3G+
Caco-2	MVLLbY5ie2ViQYPzZZk>	NYXISnJXPi5\|MjDuUUB1dyB4M{Kg{txO	MkXYOEBp	MnHsSG1UVw>?	MX\FfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzVid3n0bEBKSzVyIH;mJFEzNjZizszN	M2Pj[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzPFQxLz5{MEG0N\|g1ODxxYU6=
Caco-2	MnX0T4lv[XOnIFHzd4F6	MYS2MlMzKG6PIITvJFY{OiEQvF2=	M1fLd\|QhcA>?	NIW5dpdFVVOR	M4XZZ2V5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNzD3bZRpKEmFNUCgc4YhPDFizszN	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{i0NEc,OjBzNEO4OFA9N2F-
Caco-2	NWHweFFsU2mwYYPlJGF{e2G7	NX7QcHBTOC5\|MU[gcm0hfG9iM{GuOkDPxE1?	MXm0JIg>	MVrEUXNQ	M4PlRmV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNh?=	M1vqbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzPFQxLz5{MEG0N\|g1ODxxYU6=
HepG2	M4DWVWtqdmG\|ZTDBd5NigQ>?	NHHtcVk2KM7:TR?=	MYW2bC=>	MmC2SG1UVw>?	M36xZmlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgZYNmfHmuYYTpc44>	NF3ORoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|g1OCd-MkCxOFM5PDB:L3G+
HepG2	Ml33T4lv[XOnIFHzd4F6	NF7ySms2KM7:TR?=	Mni1Oog>	NXnMWodZTE2VTx?=	MUfJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHj5dIVz[WOndInsZZRqd25?	M{XlSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzPFQxLz5{MEG0N\|g1ODxxYU6=
HepG2	NH:3Nm5McW6jc3WgRZN{[Xl?	NEDiO3E2KM7:TR?=	MkS5Oog>	MnTaSG1UVw>?	NGHEZXhKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBidHCqYT30eYJ2dGmwIHHj[ZR6dGG2aX;u	M{j1UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzPFQxLz5{MEG0N\|g1ODxxYU6=
HepG2	NVXqWItuU2mwYYPlJGF{e2G7	NWWyWmp1PSEQvF2=	M3zLRlZp	NF3LSGZFVVOR	MoL6TY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgTFMwUDRiaHnzeI9v\SCjY3X0fYxifGmxbh?=	MmroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO4OFAoRjJyMUSzPFQxRC:jPh?=
COLO205	M3jiTGtqdmG\|ZTDBd5NigQ>?	MWWxNEDPxE1?	M1XzdFI1KGh?	NVXHOYtLTE2VTx?=	MV7Jcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizJIFk\XS7bHH0bY9vKHerdHigTWM2OCCxZjCyMlIh\|ryP	NGTN[FY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES1NVM4QCd-MkC0OVE{Pzh:L3G+
SCC4	M4\CfWtqdmG\|ZTDBd5NigQ>?	NIfRNIMyKM7:TR?=	M3ntXVI1cA>?		NGrRcI9KdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6geJVjfWyrbjDhZ4V1gWyjdHnvci=>	NWOzNYhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OVIzOjVpPkKwOFUzOjJ3PD;hQi=>
SCC4	NYj5eZY2U2mwYYPlJGF{e2G7	MkPRNUDPxE1?	M2TtUVI1cA>?		M3;rb2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIHHj[ZR6dGG2aX;u	MkTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2NUKyNlUoRjJyNEWyNlI2RC:jPh?=
SCC4	NVzEUFg5TnWwY4Tpc44hSXO\|YYm=	Ml\oNUDPxE1?	NFn4c4M2KG2rbh?=		MmSxRYdwdmm\|dDDhZ5Rqfmm2eTDheEBXTFJiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEO\UEK0JIdmdmViZYjwdoV{e2mxbh?=	M2r0TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEWyNlI2Lz5{MES1NlIzPTxxYU6=
NB4	M2XGbmZ2dmO2aX;uJGF{e2G7	M1\qXFUh\|ryP	NVi3cY9DOjRiaB?=	MmSwSG1UVw>?	MV\D[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjY3P1cZVt[XSrb36gZZQheHKnLVexJJBp[XOn	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR7MUS0NEc,OjB2OUG0OFA9N2F-
NB4	MmDQT4lv[XOnIFHzd4F6	NUTTboJJPSEQvF2=	MnnsNlQhcA>?	MnXqSG1UVw>?	M1\USmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4V1gWyjdHWgeJVjfWyrbjDs[ZZmdA>?	NUS3dXdYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0PVE1PDBpPkKwOFkyPDRyPD;hQi=>
NB4	NYDhPVZyTnWwY4Tpc44hSXO\|YYm=	NHXRUmk2KM7:TR?=	MVOyOEBp	MlvISG1UVw>?	MlPyTY5lfWO2aX;uJI9nKHB{MWfBSlEwS0mSMTDlfJBz\XO\|aX;u	MkHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2OUG0OFAoRjJyNEmxOFQxRC:jPh?=
NB4	MnX0T4lv[XOnIFHzd4F6	NX2xPXZyPSEQvF2=	NGHlRW4zPCCq	NUnmUoFzTE2VTx?=	NVTZT\|JWUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMh[WOndInsZZRqd25?	NWWwVmRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0PVE1PDBpPkKwOFkyPDRyPD;hQi=>
NUGC3	Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jiRWdKPTB;Mj65OEDPxE1?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh3MEm3NUc,OjB6NUC5O\|E9N2F-
A549	M4XhZ2Z2dmO2aX;uJGF{e2G7	MX61JO69VQ>?	MWOzJIg>	MVnEUXNQ	M4PZNmlv\HWldHnvckBw\iCjdYTvdIhi\3liaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=>	NF\vUZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi1OVIxQCd-MkC4OVUzODh:L3G+
HUT78	NWLMWVdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4TqcFczKGh?	NEfwTXdFVVOR	M1jPPWdKPTB;MD6zJO69VQ>?	M3P1NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEi0NlA5Lz5{MEi4OFIxQDxxYU6=
U937	NGPlcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlL1O\|IhcA>?	NU[4R20yTE2VTx?=	MnPFS2k2OD1yLkO5JO69VQ>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6NEKwPEc,OjB6OESyNFg9N2F-
A431	NH;XZ2lEgXSxdH;4bYMhSXO\|YYm=		NGC3TlA4OiCq		MkDQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDFS2ZTKHerdHigTWM2OCCxZjC0MlIh\|ryP	MkDKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOEC2NlkoRjJzMEiwOlI6RC:jPh?=
A549	NH7ZeY9EgXSxdH;4bYMhSXO\|YYm=		M2X5c\|czKGh?		NVTyR2VtS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTEGFIIfpeIghUUN3MDDv[kAyNjhizszN	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6ME[yPUc,OjFyOEC2Nlk9N2F-
CAL27	NXroVVlPS3m2b4TvfIlkKEG\|c3H5		M2e1elczKGh?		NXzwbGY5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0GOMkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEmFNUCgc4YhOy5{IN88US=>	MlPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOEC2NlkoRjJzMEiwOlI6RC:jPh?=
HeLa	M2rCN2N6fG:2b4jpZ{BCe3OjeR?=		NVrsNGtQPzJiaB?=		M3rremN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMhd3[ncnX4dJJme3OrbnegTGRCSyC5aYToJGlEPTBib3[gNU42KM7:TR?=	M37sfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEiwOlI6Lz5{MUC4NFYzQTxxYU6=
Sf21	MYPLbY5ie2ViQYPzZZk>		NHLNe48{KGh?		NWqyW49XUW6qaXLpeIlwdiCxZjDGcIFoKHSjZ3fl[EBpfW2jbjDy[YNwdWKrbnHueEBJTEGFODDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDFwMjFOwG0>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6ME[yPUc,OjFyOEC2Nlk9N2F-
SKBR3	MoDyR5l1d3SxeHnjJGF{e2G7		NIDLUlE4OiCq		MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCyMlYh\|ryP	MlzFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOEC2NlkoRjJzMEiwOlI6RC:jPh?=
SKOV3	M1jURmN6fG:2b4jpZ{BCe3OjeR?=		M17RO\|czKGh?		MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCyMlIh\|ryP	M{T4S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEiwOlI6Lz5{MUC4NFYzQTxxYU6=
COR-L23	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFixSFQyOCEQvF2=	MnXRO\|IhcA>?	NIC1[pVFVVOR	MWLHTVUxRTFwMTFOwG0>	M3PsNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEiwOlQ4Lz5{MUC4NFY1PzxxYU6=
DU145	NFXxbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDNNVAh\|ryP	MXK3NkBp	NVHDU244TE2VTx?=	MX7HTVUxRTFwMEWg{txO	MlroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOEC2OFcoRjJzMEiwOlQ4RC:jPh?=
LoVo	NFPKXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfjNVAh\|ryP	M332OFczKGh?	NVXXRVJzTE2VTx?=	MV\HTVUxRTFwNzFOwG0>	M2q0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEiwOlQ4Lz5{MUC4NFY1PzxxYU6=
MCR5-SV2	NETye4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVqxNEDPxE1?	Mlr3O\|IhcA>?	MWLEUXNQ	M{TYVmdKPTB;Mj6xJO69VQ>?	NH7pZ3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC4NFY1Pyd-MkGwPFA3PDd:L3G+
HCT116	NYjne2F[U2mwYYPlJGF{e2G7	MnfSN\|Ah\|ryP	MmTlN\|AhcA>?	MYDEUXNQ	NVvOdFluUW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4Yh[WyyaHGteJVjfWyrbjDhZ4V1gWyjdHnvci=>	Mn;wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOEC2OFcoRjJzMEiwOlQ4RC:jPh?=
HCT116	NYDqSppbU2mwYYPlJGF{e2G7	MonSN\|Ah\|ryP	MlHXN\|AhcA>?	MljQSG1UVw>?	NUPEOJZYUW6qaXLpeIlwdiCxZjDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6ME[0O{c,OjFyOEC2OFc9N2F-
U937	NWnxNnpqU2mwYYPlJGF{e2G7	MWW1JO69VQ>?	MXOyOEBp	NUHpUIJpTE2VTx?=	Mkf3TY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6\|ZnXyZZNmKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIH;mJIFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEOgZZQhUzl?	M2PPflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkmyOFkzLz5{MUK5NlQ6OjxxYU6=
U937	M{jpSWtqdmG\|ZTDBd5NigQ>?	M2j2S\|Uh\|ryP	MkPpNlQhcA>?	M{G1V2ROW09?	NEHlTIpKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4Yh[WOndInsZZRqd25ib3[gbIl{fG:wZTDIN{BifCCNMUi=	MmjwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{OUK0PVIoRjJzMkmyOFkzRC:jPh?=
U937	NVXFOVI6U2mwYYPlJGF{e2G7	Mkj0OUDPxE1?	NHOwTm8zPCCq	MVPEUXNQ	NIDQd2JKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4YheGGwLXHj[ZR6dGG2ZXSgbIl{fG:wZTDIOEBt\X[nbB?=	NI\pdXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUK5NlQ6Oid-MkGyPVI1QTJ:L3G+
U937	NGTiVFFMcW6jc3WgRZN{[Xl?	MWO1JO69VQ>?	NELjWZUyPSCvaX6=	NEfvWm9FVVOR	NXvp[Y83UW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGirc4TvcoUhUDNiYXPleJlt[XSrb36gcIV3\Wx?	NYXEZWZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyPVI1QTJpPkKxNlkzPDl{PD;hQi=>
A2780	NVXxPYRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWPJRolqQTZiaB?=	Ml7BSG1UVw>?	NF31WJlKSzVyPUGuOlIh\|ryP	M3m3VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkO0OFMxLz5{MU[zOFQ{ODxxYU6=
COLO205	MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4[xW\|k3KGh?	NELoO4NFVVOR	NV[4eVNkUUN3ME2yMlEzKM7:TR?=	M1vXdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkO0OFMxLz5{MU[zOFQ{ODxxYU6=
Hep3B	NV74bFRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHLxcIE1QCCq	NIrsWZFFVVOR	MnvQS2k2OD1zLkKxJO69VQ>?	NITFXJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNlE1Pid-MkG3NVIyPDZ:L3G+
GM11272	NHjpcHVHfW6ldHnvckBCe3OjeR?=	NFm3Z3MyODBibl2=	MXy3NkBp	M3\abGROW09?	NHvVZoRT\WGldHn2ZZRqd25ib3[gUYVEeDJibYX0ZY51KGW6cILld5Nqd25iYYSgNVAhfG9iMUCwJI5O	MoH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6NEC3NVYoRjJzOESwO\|E3RC:jPh?=
CFBE41o	MV\LbY5ie2ViQYPzZZk>	MV[1JO69VQ>?		M1XNcmROW09?	MXjEc5dvKHKnZ4XsZZRqd25ib3[gTGRCSzdiYYSgNE4zKHSxIEWgeW0>	MoH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7OES5OVgoRjJzOUi0PVU5RC:jPh?=
CFBE41o	MnX4SpVv[3Srb36gRZN{[Xl?	NHH0NW0yKM7:TR?=	NHe3PXAzPCCq	M1Hn[2ROW09?	NYT4WFJRWmW\|dH;yZZRqd25ib3[gR2ZVWiCmZXz0ZWY2ODhibYX0ZY51KHS{YX\mbYNscW6pIITvJINmdGxic4Xy[oFk\SCjczDncJlkd2[xcn3z	NFL2W\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm4OFk2QCd-MkG5PFQ6PTh:L3G+
DU145	NGCzZ\|FMcW6jc3WgRZN{[Xl?	MUKyMlUh\|ryP	NXv2d5JoOjRiaB?=	NVe5fnIzTE2VTx?=	M2T1eWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YheDJzd3HmNUBxem:2ZXnuJIV5eHKnc4Ppc44>	M4HKN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[wNVY3Lz5{MkK2NFE3PjxxYU6=
DU145	MWjLbY5ie2ViQYPzZZk>	M3TTPVUh\|ryP	MkDMNlQhcA>?	MX3EUXNQ	MYHJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcGm\|dH;u[UBJPCCjY3X0fYxifGmxbh?=	NIrBOGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2NFE3Pid-MkKyOlAyPjZ:L3G+
DU145	NFzzUJRMcW6jc3WgRZN{[Xl?	NXTaRYJiPSEQvF2=	NIrwPYEzPCCq	NU\pcHRFTE2VTx?=	NFHH[odKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaHnzeI9v\SCKMzDofZBmemGlZYT5cIF1cW:w	NVvUbYxHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlAyPjZpPkKyNlYxOTZ4PD;hQi=>
786-0	NYDWcJFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHET\|c3NjJizszN	MYm3NkBp	NIHJN4RFVVOR	MXrHTVUxRTNwMjFOwG0>	NIPzfIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
A498	NHjYeYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYC2MlIh\|ryP	NIexZnc4OiCq	MX3EUXNQ	NXnEbJp4T0l3ME2xMlYh\|ryP	M1fPc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
A549/ATCC	NVTGfXFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vtOVYvOiEQvF2=	M3z2eVczKGh?	MljLSG1UVw>?	NGnyW5JIUTVyPUGuOkDPxE1?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
ACHN	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPiWm03NjJizszN	M2rpPVczKGh?	NUX5W2YyTE2VTx?=	MnS2S2k2OD1zLkOg{txO	NVXyemtiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
BT549	Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjYXmo3NjJizszN	MX[3NkBp	MVnEUXNQ	MlzxS2k2OD1zLkOg{txO	NWjie5Q3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
EKVX	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnrOk4zKM7:TR?=	MWO3NkBp	NILyVIdFVVOR	NGG2[nNIUTVyPUGuN{DPxE1?	MoG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
HCT15	M3;DNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXH1eZR[Pi5{IN88US=>	M1XaU\|czKGh?	MnvISG1UVw>?	NV3pbXJTT0l3ME2yMlUh\|ryP	MmrYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
HOP92	MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3pOk4zKM7:TR?=	M3vtT\|czKGh?	MoTpSG1UVw>?	M1vOXGdKPTB;NDFOwG0>	NHTMWJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
IGROV1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX22MlIh\|ryP	MVS3NkBp	MVfEUXNQ	NH3QNnBIUTVyPUGuN{DPxE1?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
LOXIMVI	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX73SpFYPi5{IN88US=>	MYG3NkBp	M{Oxd2ROW09?	MV;HTVUxRTFizszN	NHzFS5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
M14	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLOWYp[Pi5{IN88US=>	NVPUd5dPPzJiaB?=	M{npNmROW09?	M3P2dWdKPTB;MT6zJO69VQ>?	NYDMe2ViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
MALME-3M	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWi2MlIh\|ryP	M2LzR\|czKGh?	Moq4SG1UVw>?	M1eydGdKPTB;MD6zNkDPxE1?	NX;OO2JkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
MCF10A	MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlOwOk4zKM7:TR?=	NGjJdpk1QCCq	NEnTW3ZFVVOR	NYTPR4dbT0l3ME25MlYh\|ryP	NGXk[ms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
MDA-MB-435	NWS4PZNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVS2MlIh\|ryP	M4HodFczKGh?	MlPBSG1UVw>?	Mme4S2k2OD1yLkWg{txO	M{fPflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
MDA-MB-468	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU[2MlIh\|ryP	Mk\BO\|IhcA>?	M{myU2ROW09?	MVzHTVUxRTBwNkOg{txO	MnPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
MOLT4	M1LUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPp[os3NjJizszN	NUfXfVZ{PzJiaB?=	M{XZ[WROW09?	M{TFRmdKPTB;MD60JO69VQ>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
NCI-ADR-RES	NV;uWm45T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7WN2JYPi5{IN88US=>	NGHJc2Q4OiCq	MVXEUXNQ	MXjHTVUxRTBwMU[g{txO	MkDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
NCI-H23	NXm0ZmZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rsb\|YvOiEQvF2=	MoDUO\|IhcA>?	NXP3O\|FmTE2VTx?=	NVvpNIhjT0l3ME2xJO69VQ>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
NCI-H322M	MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\UWVYvOiEQvF2=	NILhWXc4OiCq	NU\K[XBtTE2VTx?=	NWT1VFJ7T0l3ME2wMlc6KM7:TR?=	MofSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
NCI-H460	M{nvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfJNZI3NjJizszN	NEPkcZM4OiCq	NGnrXGNFVVOR	MnzTS2k2OD1yLke5JO69VQ>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
NCI-H522	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorYOk4zKM7:TR?=	NFW4OXE4OiCq	MUPEUXNQ	NH74U\|JIUTVyPUCuOUDPxE1?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
OVCAR3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWC2MlIh\|ryP	NHXuSG04OiCq	MlPnSG1UVw>?	MXvHTVUxRTFwMzFOwG0>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
OVCAR4	NXPaVZlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX[2MlIh\|ryP	MWi3NkBp	MnvHSG1UVw>?	MkH6S2k2OD12IN88US=>	Ml7aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
OVCAR5	NHfwO\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrVOk4zKM7:TR?=	NXvxV3pLPzJiaB?=	NEnmPVNFVVOR	MXHHTVUxRTBwN{mg{txO	M3XF[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
OVCAR8	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnRVlc3NjJizszN	NXfTNXpkPzJiaB?=	M4jEOmROW09?	NYK2[nR4T0l3ME2wMlUh\|ryP	M{jTdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
RXF393	NVTkdXdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\NOlYvOiEQvF2=	M4exb\|czKGh?	NWPVNlhPTE2VTx?=	NEH6cWFIUTVyPUGuN{DPxE1?	MlrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
SF268	NYfXRldJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrCOk4zKM7:TR?=	MmnOO\|IhcA>?	MVzEUXNQ	MmfoS2k2OD1zLk[g{txO	NWrYVnlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
SF295	M2jpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7zeIk3NjJizszN	MUK3NkBp	M4C2S2ROW09?	NEnRfmlIUTVyPUGuOkDPxE1?	NGr3[pA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
SF539	M3XkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIC2Wo03NjJizszN	NUjjVo84PzJiaB?=	M2fJWmROW09?	MnnlS2k2OD1{IN88US=>	M{P3W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
SK-MEL-2	NYSzO4xqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jTR\|YvOiEQvF2=	M1Hre\|czKGh?	M{jCc2ROW09?	NVzZOVRbT0l3ME2xMlMh\|ryP	NGf4XlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
SK-MEL-28	NU\yfnZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DxWFYvOiEQvF2=	NHnaR484OiCq	M2PhUmROW09?	NGTkT3dIUTVyPUGg{txO	M1XDWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
SK-MEL-5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPqOk4zKM7:TR?=	MVi3NkBp	Mn7xSG1UVw>?	MkHpS2k2OD1yLk[zJO69VQ>?	NYDkNpFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
SKOV3	M2nQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEG5Wm43NjJizszN	NV\UR3hGPzJiaB?=	NWnuRZI1TE2VTx?=	MV;HTVUxRTFizszN	NHnnZ\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
SN12C	NH\GS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PK[\|YvOiEQvF2=	MmXrO\|IhcA>?	M2i5[2ROW09?	NUHxZXRoT0l3ME2yJO69VQ>?	M4LHUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
SNB19	Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY[2MlIh\|ryP	M3HLd\|czKGh?	NUDoRVlOTE2VTx?=	NEL3RpFIUTVyPUCuOlMh\|ryP	MkL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
SNB75	NVLBUpR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIKweno3NjJizszN	MVy3NkBp	NVfZbHdrTE2VTx?=	M3zMdGdKPTB;MD63PUDPxE1?	M4D5PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
SR	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXTbGE3NjJizszN	NU[xc3Q2PzJiaB?=	NYn1OItETE2VTx?=	M2SzZmdKPTB;MD60JO69VQ>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
T47D	MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVu2MlIh\|ryP	NIfuZ4g4OiCq	M4PuSWROW09?	NFnKPFVIUTVyPUCuOUDPxE1?	NUjyfZdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
TK10	M{PE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37CbVYvOiEQvF2=	M2LEXlczKGh?	NWnxTFRxTE2VTx?=	NES3[pZIUTVyPUCuOlMh\|ryP	M3X0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
UACC257	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLQVVFvPi5{IN88US=>	NVm2UmlMPzJiaB?=	NHvkRnNFVVOR	MkTkS2k2OD1yLkWg{txO	NFuzVGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
UACC62	NX3ZVWhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\2OFYvOiEQvF2=	M{DZdVczKGh?	NEDhb2hFVVOR	M4T2eGdKPTB;MD60JO69VQ>?	MmjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
UO31	NGLMS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXy2MlIh\|ryP	NUL2eYFwPzJiaB?=	M2myfWROW09?	NXmyeWxJT0l3ME2wMlUh\|ryP	NHTaO\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
Hep3B	NHviTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MojxOFghcA>?	M{i4UGROW09?	MWXHTVUxRTBwNkmg{txO	NV;6OXZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|k5PjNpPkKyOFM6QDZ\|PD;hQi=>
BE(2)-C	MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGnJSGw4OiCq	MVjEUXNQ	MVfJR\|cxRTJizszN	M4K3cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUOyN\|E3Lz5{MkmzNlMyPjxxYU6=
Bel7402	NVS5TGJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEDVelU4OiCq	MXfEUXNQ	MmTXS2k6OD1zNzFOwG0>	NWWyfpJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlE{PzZpPkKzNFYyOzd4PD;hQi=>
Bel7404	MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NITx[ng4OiCq	MmDvSG1UVw>?	NH\6T3pIUTlyPUG4JO69VQ>?	M4\OfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[xN\|c3Lz5{M{C2NVM4PjxxYU6=
BGC823	M2\BUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWPPV41GPzJiaB?=	NFPmUlNFVVOR	NVzrOG01T0l7ME23MlUh\|ryP	MojSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkGzO\|YoRjJ\|ME[xN\|c3RC:jPh?=
MGC803	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWm3NkBp	NWT2ToY2TE2VTx?=	MkexS2k6OD1zMD64JO69VQ>?	NV60SpZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlE{PzZpPkKzNFYyOzd4PD;hQi=>
SGC7901	M{jPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkniO\|IhcA>?	NFLIe5NFVVOR	NEftSXdIUTlyPUmuOEDPxE1?	NUPoRpptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlE{PzZpPkKzNFYyOzd4PD;hQi=>
SKHEP1	MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHPuUok4OiCq	NWPJZ2loTE2VTx?=	NW\NV\|BjT0l7ME2xO{DPxE1?	NVu0fXhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlE{PzZpPkKzNFYyOzd4PD;hQi=>
SMMC7721	NXviW45kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NInvOYw4OiCq	NWXHdYNSTE2VTx?=	NF\IWXRIUTlyPUKwJO69VQ>?	M2DFclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[xN\|c3Lz5{M{C2NVM4PjxxYU6=
NUGC3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jhXlExKM7:TR?=			NV\vSI5qT0l;Mj65OEDPxE1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF4M{OzNkc,OjNzNkOzN\|I9N2F-
A2780 CisR	MXPLbY5ie2ViQYPzZZk>		NYDQXG96OThiaB?=		MojyTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkS0JO69VQ>?	M2TXV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkWyOlA{Lz5{M{K1NlYxOzxxYU6=
CAL27 sens	M{XqWGtqdmG\|ZTDBd5NigQ>?		MVKxPEBp		M2rkRWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD6zOkDPxE1?	Mo\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ\|MkWyOlA{RC:jPh?=
CAL27 CisR	MmjOT4lv[XOnIFHzd4F6		MVexPEBp		MUTJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO	NWfCe\|lZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOVI3ODNpPkKzNlUzPjB\|PD;hQi=>
KYSE-510 CisR	MkC0T4lv[XOnIFHzd4F6		MmLhNVghcA>?		MoTiTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkW5JO69VQ>?	NHTwNHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1NlYxOyd-MkOyOVI3ODN:L3G+
KYSE-510 sens	Mlr4T4lv[XOnIFHzd4F6		NYrzNZZ[OThiaB?=		M132XGlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD63JO69VQ>?	M2fpOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkWyOlA{Lz5{M{K1NlYxOzxxYU6=
MDA-MB-231 sens	MVHLbY5ie2ViQYPzZZk>		NVPodlJ1OThiaB?=		M2HuU2lvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	MknXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ\|MkWyOlA{RC:jPh?=
MDA-MB-231 CisR	NUnpT4ZqU2mwYYPlJGF{e2G7		MUexPEBp		NUPMbXR2UW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlYyKM7:TR?=	NVywTnB4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOVI3ODNpPkKzNlUzPjB\|PD;hQi=>
ES2	NXz6ZmRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHnXNpg1QCCq	MUPEUXNQ	NFLZ[YhKSzVyPUGyMlch\|ryP	NWnlTIVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM1PDlpPkKzOFk{PDR7PD;hQi=>
MDA-MB-231	M{fIdmtqdmG\|ZTDBd5NigQ>?	MXqxNEDPxE1?	MmrsN\|AhdWmw	MlyySG1UVw>?	MoK5TY5pcWKrdHnvckBw\iCKRFHDNoE>	MlH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUO0OFkoRjJ\|NEmzOFQ6RC:jPh?=
MDA-MB-231	M3rKd2tqdmG\|ZTDBd5NigQ>?	MmL1NUDPxE1?	NXjSe5h5OjRiaB?=	NWT5OpY4TE2VTx?=	NYTQVnN2UW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDhZ4V1gWyjdHnvckBt\X[nbIOgc4YhfHWkdXzpci=>	M2fLeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEmzOFQ6Lz5{M{S5N\|Q1QTxxYU6=
HS68	MX3DfZRwfG:6aXOgRZN{[Xl?	MoPXNVAh\|ryP	Mn7jO\|IhcA>?	MkDXSG1UVw>?	NI\IXW5KSzVyPUSuOkDPxE1?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5MEW0Nkc,OjN3N{C1OFI9N2F-
MEF	M4\OSWN6fG:2b4jpZ{BCe3OjeR?=	M1nlNFExKM7:TR?=	NV75e5dXPzJiaB?=	NX\rbVJMTE2VTx?=	Mn\uTWM2OD12LkSg{txO	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5MEW0Nkc,OjN3N{C1OFI9N2F-
BGC823	M2qzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVntd5B6TE2VTx?=	M2TFRmdKPTB;Mz6wPUDPxE1?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZyMUewOkc,OjN4MEG3NFY9N2F-
High5	NV3kO4MxU2mwYYPlJGF{e2G7		NUfSSZBqOjRiaB?=		NV\iSFl4UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEPiC5aYToJGlEPTBib3[gNE4xQSEQvF2=	MkKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MEK1NlMoRjJ\|NkCyOVI{RC:jPh?=
High5	MVHLbY5ie2ViQYPzZZk>		MlPWNlQhcA>?		MnK2TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDNUB4cXSqIFnDOVAhd2ZiMD6xNkDPxE1?	NYKzeXlyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NFI2OjNpPkKzOlAzPTJ\|PD;hQi=>
High5	MmrPT4lv[XOnIFHzd4F6		NIntOHYzPCCq		M2fId2lvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Mhf2m2aDDJR\|UxKG:oIECuNVch\|ryP	MoPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MEK1NlMoRjJ\|NkCyOVI{RC:jPh?=
A549	NGDNb\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NICwVnJFVVOR	NFe0SFNKSzVyPUGuNFc6KM7:TR?=	MkD0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4NESyNVAoRjJ\|NkS0NlExRC:jPh?=
HCT116	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXLiNnFrTE2VTx?=	M1XieGlEPTB;MD63OVch\|ryP	NFL2[IE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[0OFIyOCd-MkO2OFQzOTB:L3G+
K562	Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mn7OSG1UVw>?	MV;JR\|UxRTBwNkS1JO69VQ>?	NGjvVHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[0OFIyOCd-MkO2OFQzOTB:L3G+
GBC-SD	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjF[Zk2KM7:TR?=	MWK3NkBp	M2XXTWROW09?	NYnibZl2UUN3ME2xOE45KM7:TR?=	M2i2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C3NlYxLz5{M{ewO\|I3ODxxYU6=
HGC27	MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPUV29DPSEQvF2=	MWq3NkBp	NWniZWtMTE2VTx?=	NHmzOIRKSzVyPUWuOEDPxE1?	NHvoOXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewO\|I3OCd-MkO3NFczPjB:L3G+
HL60	MnTXT4lv[XOnIFHzd4F6	MXS1JO69VQ>?	Ml70NlQhcA>?	MXrEUXNQ	M1jve2lvcGmkaYTpc44hd2ZiSFTBRy=>	MoizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MEeyOlAoRjJ\|N{C3NlYxRC:jPh?=
Vero	M{iyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV:3NkBp	MnPkSG1UVw>?	MXfJR\|UxRTBwOTFOwG0>	NGTMbWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4OlQ2Oid-MkO3PFY1PTJ:L3G+
NCI60	MmG4R5l1d3SxeHnjJGF{e2G7		NHuwbpg1QCCq	MX3EUXNQ	NHHXTnRIUT1yLkWzJO69VQ>?	NHuzTZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxOVMzPyd-MkSwNVU{Ojd:L3G+
SW620	NXz4WFZOS3m2b4TvfIlkKEG\|c3H5		MYG0PEBp	MXvEUXNQ	MVnHTV0xNjV2IN88US=>	Mo[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUWzNlcoRjJ2MEG1N\|I4RC:jPh?=
U251	M4PUbGN6fG:2b4jpZ{BCe3OjeR?=		M2\jTVQ5KGh?	MnfsSG1UVw>?	M1LGTWdKRTFwNUOg{txO	NH;hR2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxOVMzPyd-MkSwNVU{Ojd:L3G+
KM12	MWrDfZRwfG:6aXOgRZN{[Xl?		M{TBZlQ5KGh?	M3L1VmROW09?	NXew[JBsT0l;MT64PEDPxE1?	M1f1V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG1N\|I4Lz5{NECxOVMzPzxxYU6=
Hs578T	MUfDfZRwfG:6aXOgRZN{[Xl?		MVe0PEBp	MmTTSG1UVw>?	NEHmbI1IUT12LkizJO69VQ>?	NFHETI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxOVMzPyd-MkSwNVU{Ojd:L3G+
MDA-MB-231	M{nBZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoPVOFghcA>?		NIXlXllKSzVyPUCuNVYh\|ryP	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7NUCxOkc,OjRyOUWwNVY9N2F-
MCF7	NG\ReYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFn2cIE1QCCq		NFjIenFIUT1yLkS1JO69VQ>?	M1fYTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUG5OVU2Lz5{NEGxPVU2PTxxYU6=
MDA-MB-435	M1vkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{m2UlQ5KGh?		NIiwZotIUT1yLki4JO69VQ>?	MlvDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUm1OVUoRjJ2MUG5OVU2RC:jPh?=
AsPC1	NHTybVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVraVHg1OzBizszN	NFPRTnM1QCCq	NYDJe25TTE2VTx?=	M2K5XGlEPTB;Mz62OkDPxE1?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF6NUO3PEc,OjRzOEWzO\|g9N2F-
Jurkat E6.1	NED2VGhMcW6jc3WgRZN{[Xl?		NVvwO3dPOiCq	MmXESG1UVw>?	MoLkTY5pcWKrdHnvckBw\iCKRFHDOEB4cXSqIFnDOVAhd2ZiMD6wOEDPxE1?	NHf5boM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK2NVg3Oid-MkSyOlE5PjJ:L3G+
KG1	MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NELNTJU1QCCq		MUfJR\|UxRTFwMUWg{txO	MoHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MkWwNFMoRjJ2NUK1NFA{RC:jPh?=
HEL	Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1G3WlQ5KGh?	NIO0[ldFVVOR	NUGxdIdCUUN3ME2wMlQ6KM7:TR?=	Mkn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OUSwOVUoRjJ2Nkm0NFU2RC:jPh?=
HSC3	M3r1[2N6fG:2b4jpZ{BCe3OjeR?=		Mln1NVIhcA>?	MVLEUXNQ	M1u0SWlEPTB;MD63NUDPxE1?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4NkW2NEc,OjR5Nk[1OlA9N2F-
HT-29	MVPDfZRwfG:6aXOgRZN{[Xl?		MYqxNkBp	M{X2b2ROW09?	MYPJR\|UxRTBwN{Kg{txO	NUf1NmI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlY2PjBpPkK0O\|Y3PTZyPD;hQi=>
KB	NX\TO4VHS3m2b4TvfIlkKEG\|c3H5		MUSxNkBp	NIPrbo5FVVOR	NXH1[2FyUUN3ME2wMlc2KM7:TR?=	NXTHO4tKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlY2PjBpPkK0O\|Y3PTZyPD;hQi=>
H460	M{\CXmN6fG:2b4jpZ{BCe3OjeR?=		MmTkNVIhcA>?	NFnMdZVFVVOR	MYPJR\|UxRTBwOEKg{txO	M3XtXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[2OVYxLz5{NEe2OlU3ODxxYU6=
MONE1	M1jsO2N6fG:2b4jpZ{BCe3OjeR?=		NH65dVAyOiCq	MoX2SG1UVw>?	MXnJR\|UxRTFwMUig{txO	NXH1dIJSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlY2PjBpPkK0O\|Y3PTZyPD;hQi=>
MKN45	NXvG[4x3S3m2b4TvfIlkKEG\|c3H5		MnO0NVIhcA>?	MVPEUXNQ	NYXhT3E5UUN3ME2xMlI2KM7:TR?=	M{DB[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[2OVYxLz5{NEe2OlU3ODxxYU6=
TSGH	NGOycldEgXSxdH;4bYMhSXO\|YYm=		MlLtNVIhcA>?	NFnwPG5FVVOR	NX\w[IlsUUN3ME2yMlA6KM7:TR?=	NVfhWG5[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlY2PjBpPkK0O\|Y3PTZyPD;hQi=>
HL60	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmTlO\|IhcA>?	M17qZ2ROW09?	MWrHTVUxRTBwOUOg{txO	NGPaTYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFUxOCd-MkS5NFA2ODB:L3G+
HEK293	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4m5XFczKGh?	NXXUWWF{TE2VTx?=	MYnHTVUxRTF\|IN88US=>	MljpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC1NFAoRjJ2OUCwOVAxRC:jPh?=
Jurkat	M1vPfmN6fG:2b4jpZ{BCe3OjeR?=	MnvxNVAxKM7:TR?=	MX63NkBp		NEHBfnhIUTVyPUCuPUDPxE1?	Moq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3OFMoRjJ2OUCwO\|Q{RC:jPh?=
GM15850	NIDnfXBMcW6jc3WgRZN{[Xl?	M2PYNVIvPSEQvF2=	NVPFWZR5QTZiaB?=	MX\EUXNQ	NH\pTmhld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCueYPpcoUhOTRiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	NFjTdVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmyNVM3Pyd-MU[5NlE{Pjd:L3G+
GM15850	NYO2eG41U2mwYYPlJGF{e2G7	M3rlO\|IvPSEQvF2=	NWTKRmd1QTZiaB?=	M2DmVGROW09?	MnPi[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFUh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M{LzXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
GM15850	Mnz5T4lv[XOnIFHzd4F6	MUWyMlUh\|ryP	MoX6PVYhcA>?	MVLEUXNQ	Mm\J[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFEzKGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NIrheHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmyNVM3Pyd-MU[5NlE{Pjd:L3G+
GM15850	MX\LbY5ie2ViQYPzZZk>	MorNNk42KM7:TR?=	NG\sU5Q6PiCq	M1zzfmROW09?	MlTi[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M{mz[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
GM15850	NVvHXVdtU2mwYYPlJGF{e2G7	M3rhdFIvPSEQvF2=	MXS5OkBp	M{\nU2ROW09?	MmLq[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFgh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NEnoe2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmyNVM3Pyd-MU[5NlE{Pjd:L3G+
GM15850	NEfm[YVMcW6jc3WgRZN{[Xl?	M1f2eFIvPSEQvF2=	NVP6WIk5QTZiaB?=	MluzSG1UVw>?	MW\kc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVYh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjl{MUO2O{c,OTZ7MkGzOlc9N2F-
GM15850	NFzSRXhHfW6ldHnvckBCe3OjeR?=	NFziXWg2KM7:TR?=	NGPqeo4yOiCq	M3v2ZWROW09?	NVTkRpdCcGG\|IH7vJIVn\mWldDDvckBHYE5ibWLORUBmgHC{ZYPzbY9v	M{PiZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
U937	MXHLbY5ie2ViQYPzZZk>	MoDlOUDPxE1?	MlTXNlQhcA>?	NW\le2R{TE2VTx?=	MlvvbIF{KG6xIHXm[oVkfCCxbjDhcJBp[SC2dXL1cIlvKGGlZYT5cIF1cW:w	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR2N{e1NEc,OTd2NEe3OVA9N2F-
U937	M4Xz[GtqdmG\|ZTDBd5NigQ>?	MnXvNUDPxE1?	MoT4NlQhcA>?	MXfEUXNQ	MmnzbIF{KG6xIHXm[oVkfCCxbjDhcJBp[SC2dXL1cIlvKGGlZYT5cIF1cW:w	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR2N{e1NEc,OTd2NEe3OVA9N2F-
PANC1	NHTSNJJHfW6ldHnvckBCe3OjeR?=	M3W3V\|Eh\|ryP	MnTYNlQhcA>?		NUHNSXdQ\G:nczDuc5QhcW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	NIG5eVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W4PFc1PCd-MUe1PFg4PDR:L3G+
PANC1	MnuySpVv[3Srb36gRZN{[Xl?	NHzxXo0yKM7:TR?=	M2LQW\|Q5KCCq		Mlez[I9meyCwb4SgbY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV6OEe0OEc,OTd3OEi3OFQ9N2F-
Caco-2	MonQSpVv[3Srb36gRZN{[Xl?	NV7WS4dEPSEQvF2=	NXrHPHhrOjRiaB?=	NFT0bW9FVVOR	NXnwXWtQ\G:nczDuc5QhcW6mdXPlJHAzOVeDRkGg[4Vv\SCneIDy[ZN{cW:w	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{i0NEc,OjBzNEO4OFA9N2F-
SCC4	Mly5SpVv[3Srb36gRZN{[Xl?	MWqxJO69VQ>?	MlP4NVAhdWmw	NUfIWW5PTE2VTx?=	MkPvbIF{KG6xIHHnc45qe3RiYXP0bZZqfHliYYSgWmRTKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBEYVB{NDDn[Y5mKGW6cILld5Nqd25?	NGfaXHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES1NlIzPSd-MkC0OVIzOjV:L3G+
A549	NFXGR4tHfW6ldHnvckBCe3OjeR?=	MmrsOUDPxE1?	NVqxW4tbOyCq	NVXpSmV1TE2VTx?=	M1z1VoRw\XNibn;0JIlv\HWlZTDheZRweGijZ4mgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iTFOzTWk>	NHrGO2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi1OVIxQCd-MkC4OVUzODh:L3G+
HCT116	NEP3UnVMcW6jc3WgRZN{[Xl?	MmfnNE4{KM7:TR?=	MlTJN\|AhcA>?	M1zSOmROW09?	NUn0OY9t\G:nczDuc5QhcW6qaXLpeEBJTEGFMTDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKM1u5JIFk\XS7bHH0bY9v	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6ME[0O{c,OjFyOEC2OFc9N2F-
HepG2	M17CZWZ2dmO2aX;uJGF{e2G7	M3;EcVExKM7:TR?=	MVSyOEBp	MUXEUXNQ	MlXo[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BpgXCncnHj[ZR6dGG2aX;uJI9nKHB3Mx?=	NYLjUIcxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1OFg2QDJpPkKxOVQ5PTh{PD;hQi=>
GM11272	M3HEfGZ2dmO2aX;uJGF{e2G7	M2nSO\|AvOSEQvF2=	NEDYSmg4OiCq	NWK5VZBjTE2VTx?=	NInvbI9ld2W\|IH7veEBz\WGldHn2ZZRmKE2nQ4CyJI12fGGwdDDlfJBz\XO\|aX;u	M1nKTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOESwO\|E3Lz5{MUi0NFcyPjxxYU6=
MDA-MB-231	NFOydJBMcW6jc3WgRZN{[Xl?	MlruNVAh\|ryP	Ml3nOUBucW5?	NYfGSoFpTE2VTx?=	MkjY[I9meyCwb4SgbY5pcWKrdDDISGFEOmF?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7M{S0PUc,OjN2OUO0OFk9N2F-
MDA-MB-231	MYLLbY5ie2ViQYPzZZk>	NXnpSHc4OSEQvF2=	NXLiOGVVOjRiaB?=	MUDEUXNQ	NVPtcGlo\G:nczDuc5QhcW6qaXLpeEBJTEGFNjDhd5Nme3OnZDDhd{Bi[2W2eXzheIlwdiCuZY\lcJMhd2ZidIXieYxqdg>?	NUjEZnNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM1PDlpPkKzOFk{PDR7PD;hQi=>
K562	NGLvZW5McW6jc3WgRZN{[Xl?				MVzkc4V{KG6xdDDpcohq[mm2IFjERWM>	NET1VGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W5NVEyOSd-MkO1PVEyOTF:L3G+
Jurkat	NV74cZFTS3m2b4TvfIlkKEG\|c3H5	M1v6b\|IxKM7:TR?=	MmHiO\|IhcA>?	NVv3U2ZJTE2VTx?=	NHHw[VlvdyCleYTveI95cWOrdImgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44>	NWPCOHlNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNFQ{PDhpPkK0N\|A1OzR6PD;hQi=>
HCT116	M{HF[mFxd3C2b4Ppd{BCe3OjeR?=	NYD1ZlJTOyEQvF2=	MXWyOEBp	NFvKWGNFVVOR	Mlf4[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCyNUOgdJJwfGWrbjDs[ZZmdA>?	M3y1VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[2OVYxLz5{NEe2OlU3ODxxYU6=
KASUMI-1	NH30[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;tTWM2OD17OT6xO{BvVQ>?	NHu4OJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
KARPAS-45	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnq3TWM2OD1zN{OuPFkhdk1?	NGjGPJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
BHT-101	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3IOXlKSzVyPUK0OE4yQCCwTR?=	M3nReVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
H9	M1rFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLOTWM2OD1{NUWuNFQhdk1?	M1rJO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
PA-1	M4TrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTJ6Nj6yOkBvVQ>?	NILwTWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NEC8	NYjYZ\|BXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHpTWM2OD1{OEmuN\|ghdk1?	M1rxUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MHH-PREB-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTJ7ND61N{BvVQ>?	M2HHXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NB7	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LVTWlEPTB;M{S1Mlc1KG6P	NX7IdFJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
A3-KAW	NYrDfGtST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfNcFduUUN3ME20NFAvPTlibl2=	MoTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NB69	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mor6TWM2OD12MUGuO\|Ehdk1?	NE[wc4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
EoL-1-cell	NIjqbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHKbmpKSzVyPUS1OFI2KG6P	NGjoPHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
CHP-212	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHT5VoRKSzVyPUS1O{42OyCwTR?=	NHL6eWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
C2BBe1	NYS1OHlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LOWWlEPTB;NEeyMlE6KG6P	M1f4Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
697	M1PRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTR5Mz60NUBvVQ>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
BCPAP	MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvQdGtKSzVyPUWwNU41OiCwTR?=	MkDVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
L-363	NV73[IRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrETotKSzVyPUWwN{4yKG6P	Mn[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
ES8	NH3WVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPSO4g1UUN3ME21NlMvPTNibl2=	NWmybYM3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
BE-13	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfWNJFnUUN3ME21NlYvQTZibl2=	NHXMZ2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
CTB-1	M2TOWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXQWnNVUUN3ME21N\|cvQTJibl2=	M1Hkb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
HD-MY-Z	M1G5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXpTWM2OD13M{iuNVMhdk1?	MljEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NKM-1	NFi5T3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTV2ND6yO{BvVQ>?	M1X2W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H720	NYiyToJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1W2e2lEPTB;NU[wMlE5KG6P	MnqxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
KY821	Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\lTWM2OD13NkOuNlUhdk1?	NIfhNpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
OVCAR-5	MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\WOZhKSzVyPUW3Ok4yOSCwTR?=	M2Pz[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
CTV-1	MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnGeldKSzVyPUW4NU42PiCwTR?=	NV7VPWFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
P12-ICHIKAWA	Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nZWWlEPTB;NUm2MlUyKG6P	NEXwO2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
DB	M1;GN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvaTWM2OD13OUiuOVchdk1?	NFzLNlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
CHL-1	NIDnV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHITWM2OD14NEKuNFghdk1?	M3rZSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
A4-Fuk	MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jFc2lEPTB;NkS0MlkyKG6P	NYPUVJRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
MV-4-11	M2K4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXS1fpF1UUN3ME22OVkvOSCwTR?=	MmK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
RPMI-8226	M2nzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3B[op2UUN3ME22O\|gvOThibl2=	MnHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NB14	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4iwW2lEPTB;Nkm2Mlk2KG6P	M{PYUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
DOHH-2	NXfLTHBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTdyNj62PEBvVQ>?	M1m1R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
D-423MG	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTXfpVKSzVyPUewOk45QSCwTR?=	M3X6PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
D-283MED	NYrv[GN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWT0cXI5UUN3ME23NVQvOTRibl2=	MlfMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
ES1	NYSyRXk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTd{ND60JI5O	NWXZZ41DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
GOTO	MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7OTWM2OD15MkmuNVIhdk1?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NCI-H209	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF[0bFZKSzVyPUeyPU46KG6P	MmHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
MOLT-13	M335[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NED6[YxKSzVyPUezPE46QCCwTR?=	M2DrO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
ATN-1	M3P3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnMN\|FKSzVyPUe0NE4zQCCwTR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
DU-4475	NV\2e2EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTd3MT65NUBvVQ>?	NXrhZ5NTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NB10	MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3flTGlEPTB;N{WxMlkzKG6P	NWSxUlNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
KG-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlK4TWM2OD15N{WuOFUhdk1?	NF3uUlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
MOLT-4	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHS3O\|BKSzVyPUe4O{41PiCwTR?=	MknDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
TE-1	MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTd7MT6xJI5O	NYrJT2dFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SBC-1	NX74Zo13T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\CTWM2OD15OUOuPFQhdk1?	NGXCU3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HEL	M1jUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{K0emlEPTB;OEC2MlA5KG6P	NHLnOWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SK-MEL-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXCfldKSzVyPUiwPU41PCCwTR?=	MlLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
KU812	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHGzboZKSzVyPUixN{4yKG6P	M2n6WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
RPMI-8866	NF;IRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRThzMz62O{BvVQ>?	MlyxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
ALL-PO	M{H4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRThzND62OkBvVQ>?	NUXjPVk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
LU-139	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmK0TWM2OD16MkKuPFYhdk1?	NWLhfFJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
RS4-11	Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3X5dmlEPTB;OEOyMlQ2KG6P	Mlv3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
EW-18	NIT3e3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTh\|Mj65OkBvVQ>?	NHLuSG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
P30-OHK	NVzlUFRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jlbGlEPTB;OEO1Mlchdk1?	M1HQblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
D-566MG	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHVbZFKSzVyPUizPE43OiCwTR?=	NXzXNZdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HSC-4	Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzDWXFKSzVyPUi0Ok42OSCwTR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
QIMR-WIL	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlG0TWM2OD16NkKuNFMhdk1?	NVSzPJFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SW954	Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{T5SWlEPTB;OE[zMlE3KG6P	M{\TflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
HGC-27	M{izR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWe5SWh{UUN3ME24O\|IvOzRibl2=	M13E[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
HH	M1PsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1u0bWlEPTB;OEm0MlEzKG6P	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
KE-37	M1PrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TINmlEPTB;OEm0MlYzKG6P	Mlz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SK-N-DZ	NWrXWVFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTlyMD60N{BvVQ>?	MkHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
J-RT3-T3-5	NITBTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTlzMD60PUBvVQ>?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
A427	NXjlWYl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTl{MD64OEBvVQ>?	NH\qWWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
ECC10	M3;Oc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzjTWM2OD17NEWuPFchdk1?	M2fOPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
EW-1	Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTl2Nz6yOkBvVQ>?	MnjiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
MIA-PaCa-2	M1zTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXCTWM2OD17NEmuNVIhdk1?	NHr3foE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HCC2218	NW[z[pJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnP2TWM2OD17NUiuOFghdk1?	NHHLSZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HAL-01	NIHuWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjUVJpCUUN3ME25OlgvODRibl2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
RD	MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rpbGlEPTB;OUe0MlQ2KG6P	NHTPPFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SK-N-AS	NHG0b2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\RU2lEPTB;OUi4MlEhdk1?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
ML-2	NFLMTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoqzTWM2OD1zLkCwOFA4KM7:TR?=	M4jDSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MEL-HO	MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUWzUpExUUN3ME2xMlAxPTh{IN88US=>	M3jhRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MS-1	Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTFwMEC2NVch\|ryP	Ml30QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-SNU-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\NRWlHUUN3ME2xMlAzOzNzIN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
8505C	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?

研究领域

产品类型